

Index

Note: page numbers with suffix ‘f’ refer to figures and those with suffix ‘t’ refer to tables; chemicals listed under the main name, not the prefix such as Greek letter.

ABCB4 mutations (MDR3) 25, 115 progressive familial intrahepatic disease 208–11	ABCB11 mutations (BSEP) 20–1, 25, 115 progressive familial intrahepatic disease 204–5, 207, 210–11	ABCG8 cholesterol hemitransporter polymorphisms 259	ABO incompatibility in neonatal jaundice 186	aceruloplasminemia 467, 470	acetaminophen acute liver failure in children 34–5, 41, 43f detoxification defects 349 drug-induced liver disease 347–9 formulations 349 hepatotoxicity 349f mechanism 348–9 resistance in young children 349 therapeutic misadventure 348–9 treatment 347–8, 362	acetyl CoA 587, 606	acetyl CoA carboxylase 14	acid sphingomyelinase deficiency 552–3	acid–base disturbances 46–7	acquired immunodeficiency syndrome (AIDS) 148	actinomycosis (<i>Actinomyces israeli</i>) 680	activated partial thromboplastin time (PTT) 94	acute fatty liver of pregnancy 600, 617–18	acute intermittent porphyria 514–17 clinical features 514–16	diagnosis 515–16 gene therapy 517 homozygous dominant 517 liver transplantation 517 treatment 517	acute liver failure in children 32–49 cerebral oedema 45–6 clinical characterization 32–3 clinical course 33f complications 44–7 cardiopulmonary 47 central nervous system 44–6 gastrointestinal 46 hematologic 46 infections 47 metabolic 46–7 renal 46 definition 32 diagnosis 39–41 disease severity assessment 47 drug and toxin induced 34t, 34–6, 40–2 immune response 42 pathology 43f encephalopathy association 763 etiology 33t, 33–41, 34t, 39f drug and toxin-induced 34t, 34–6, 40–2, 43f immune dysregulation 36, 40 infectious diseases 37–8, 40 inherited metabolic disease 36–7, 37t, 39–40, 43f fluid administration 44, 47 frequency 32 hepatic encephalopathy 32, 44–5 hepatitis viruses 37–8 histology 42–4, 43f history taking 39 immune dysregulation 36, 371 immunology 41 indeterminate (I-pediatric ALF) 38–9	infectious diseases 37–8, 40, 42, 47 inflammatory infiltrate 44 inherited metabolic disease 36–7, 37t, 39–40 pathology 43f, 43–4 jaundice onset 32 laboratory tests 39, 44 liver cell necrosis 42–4 liver cell regeneration 42 liver transplantation 47–8, 763 decisions 33, 47–8 organ allocation 48 outcomes 48–9 management 32, 44 disease severity assessment 47 liver support 47 nutritional support 44, 47 mitochondrial injury 41 non-viral infectious hepatitis 38 nutritional support 44, 47 outcomes 33, 48–9 pathogenesis 41–2 physical assessment 39 plasmapheresis 763 recurrent 39 scoring systems 47 seizures 45 subtypes 32 systemic sepsis 38 vascular causes 42 viral infections (non-hepatitis) 38 Wilson disease 472, 481 acute lymphoblastic leukaemia 699 acute tubular necrosis 63t acute-phase proteins 694–5 acute phase response 27 acylcarnitine in fatty acid oxidation disorders 395–6	acyl-CoA dehydrogenase(s) 589–90 deficiency 396t acyl-CoA dehydrogenase 9 (ACAD9) 590, 594 acyl-CoA oxidase (ACOX1) 651 clinical findings 659 deficiency 652–3, 656 hepatic abnormalities 660 acyl-CoA synthetases 651 adefovir dipivoxil 288 adenosine deaminase deficiency 375 adenosine triphosphate (ATP) 14 biliary epithelium mechanosensitive pathways 421 defective generation 603 mitochondrial synthesis 605 adolescents, cholestasis 137 adrenoleukodystrophy neonatal-onset 581–2, 655, 658 pseudoneonatal 582 X-linked 582, 660 adriamycin 350 aflatoxin in Indian childhood cirrhosis 489 agar, Crigler–Najjar syndrome treatment 195 Aicardi–Goutières syndrome 149–50 Alagille syndrome 6, 104, 216–31 bile duct paucity 26, 104, 218f, 218, 225f, 226t bile duct–portal tract ratio 218 cholangiocarcinoma association 730 clinical features 216–18, 217t cardiac involvement 219t, 219–20, 220f, 226 ductular proliferation 219f facial features 223f, 223, 224f, 227 growth disorders 222, 225 hepatic features 217 neurologic 225–6
--	---	---	--	-----------------------------	--	---------------------	---------------------------	--	-----------------------------	---	--	--	--	---	---	---	--	--

Index

- ocular involvement 223–5, 224f
renal involvement 225f, 225
skeletal involvement 220f, 221f, 221–2, 222f, 227
vascular involvement 220–1, 221f, 226
diagnosis 216, 226–7, 227f
ductular proliferation 219
frequency 216
genetics 107, 216, 220, 227–31
 gene identification 229
 genetic testing 231
 genotype–phenotype correlation 229–30
 mutation analysis 229
 NOTCH signaling pathway 228–31
hepatocellular carcinoma
 association 730
histopathology 218–19, 219f
hypercholesterolemia 122
hyperlipidemia 122
liver transplantation 218, 228, 761
 survival 226
malignancy association 218
management 227–8
manganese levels in globus pallidus 136
quality of life 226
survival rate 220, 226, 228
ursodeoxycholic acid therapy 115
xanthomas 122, 123f
alanine aminotransferase (ALT)
 10, 89–90
 cirrhosis 58
 liver injury detection 88–9
 non-alcoholic fatty liver disease screening 632–3, 637–9
 serial measurement 90
albumin
 concentration in neonatal jaundice 188
 serum levels 88, 92–3
 synthesis 92
alcaptonuria 529–30
alcohol dehydrogenase 10
alcoholic liver disease, AST:ALT ratio 90
aldolase B
 activity reduced levels 444–5
 deficiency 445f
 diagnosis of hereditary fructose intolerance 446
 gene mutations 443
alemtuzumab 382
alglucosidase alfa 560
alkaline phosphatase 88
 laboratory assessment 90–1
 serum levels 90–1
allo(5 α -reduced)-bile acids 570–1
Alpers–Huttenlocher syndrome (Alpers syndrome) 611, 613–14
 clinical features 614
 gene mutations 613–14
 histopathology 614, 615f
 valproic acid hepatotoxicity association 362
alpha-fetoprotein
 levels in tyrosinemia 530–1
 tumor diagnosis 734, 736t
ALT *see* alanine amino-transferase
aluminum
 in cholestasis 136
 intestinal failure-associated liver disease 241
Amanita phalloides mushroom poisoning 35, 42
amatoxins 42
amenorrhea, adolescents with chronic liver disease 137
American Academy of Pediatrics, hyperbilirubinemia guidelines 184
amino acid(s)
 branched chain 126–7
 metabolism 12–13
 parenteral nutrition 239
 peroxisomal metabolic pathways 654–5
 placental transport 12
 plasma levels 97–8
 urine levels 97–8
amino acid disorders 387t
 laboratory testing 396–7
 newborn screening 397–8
5'-aminolevulinate
 in acute intermittent porphyria 516–17
 in variegate porphyria 520
5'-aminolevulinate dehydratase 510
5'-aminolevulinate dehydratase-deficient porphyria 514
5'-aminolevulinate synthase 509–10
 acute intermittent porphyria 514–15
 mutations in erythropoietic protoporphyria 521
 δ -aminolevulinic acid in tyrosinemia 527
aminopyrine breath test 96
amiodarone 350
ammonia
 conversion to urea 664–5
 detoxification/clearance 88, 97
 in hepatic encephalopathy 64
ammonium tetrathiomolybdate 485
amoxicillin–clavulanic acid 358
ampicillin–clavulanic acid 35–6
amylo-1,6-glucosidase 455–6
amyloidosis 703, 706
amylopectinosis *see* glycogen storage disease, type IV
ANA *see* anti-nuclear antibodies
Andersen disease *see* glycogen storage disease, type IV
anemia
 of cirrhosis 55
 iron deficiency 136
 see also aplastic anemia
angiomatous lesions 746f
angiosarcoma 741, 747f, 754–5
anorexia nervosa 705
antibiotics
 liver transplantation 773, 777
 sclerosing cholangitis treatment 335–6
anti-CD52 monoclonal antibodies 382
antifibrinolytic disorders 697
antifibrogenic agents 117–18, 432
anti-liver–kidney microsome type-1 antibodies 312
 autoimmune hepatitis-like hepatotoxicity 344–5
 autoimmune hepatitis 311
anti-IL-2 receptor antagonists 382
anti-lymphocyte globulin 382
antineoplastic drugs 350–1
anti-nuclear antibodies (ANA)
 acute liver disease in children 36
 autoimmune hepatitis 311–12
antioxidants
 in cystic fibrosis 423
 fibrosis treatment 118
 idiopathic copper toxicosis management 491
 mitochondrial hepatopathies treatment 624–6
 non-alcoholic fatty liver disease treatment 645
 Wilson disease management 485–6
antiretroviral therapy, HIV infection 149
anti-smooth muscle antibody (anti-SMA) 36
antithrombin deficiency 697
anti-thymocyte globulin 382
 α_1 -antitrypsin 400
 activity modification 405
 biosynthesis 406
 clearance 406
 and cystic fibrosis 424
 distribution 406–7
 enzyme–inhibitor bond formation 405
 expression 406
 function 404–6
 gene encoding 402–3, 403f
 mutant protein 407
 cellular adaptive responses 409–11
 protein polymerization 407–9, 411–12
 receptor molecules 406
 replacement therapy 415–16
 retention in endoplasmic reticulum 407–9, 408f, 412f
 cellular adaptive responses 409–11
 serum phenotype determination 413–14
 structure 402–4, 403f
 variants 403–4, 404t, 405t
 α_1 -antitrypsin deficiency 400–16
 accumulation theory 411–12
 autophagy role 409–10, 415
 biliary atresia differential diagnosis 413
 carcinogenesis 413
 cigarette smoking 402, 414
 diagnosis 400, 413–14
 emphysema 400, 402, 415–16
 endoplasmic reticulum degradation 412
 hepatic regeneration 413
 immune theory 411
 incidence 400–16
 liver disease 400, 401t
 cirrhosis 401
 clinical manifestations 400–2
 heterozygous phenotype 401
 liver transplantation 401
 malignancy 401
 molecular basis 412–13
 variants 401–2
 liver injury pathogenesis 411–13
 lung disease 400
 age of onset 416
 cigarette smoking 402, 414
 clinical manifestations 402
 emphysema association 400, 402
 pulmonary function in children 402
 treatment 415–16
 mechanism in PIZZ individuals 407–9
 nuclear factor-kappaB 410
 pathogenesis 400, 404t
 pathology 414f, 414
 pathophysiology 402–9
 phenotype determination 413–14
 population screening 416
 prevention 416
 single nucleotide polymorphisms 411

Index

- α_1 -antitrypsin deficiency (cont.)
 - treatment 414–16
 - α_1 -antitrypsin replacement therapy 415–16
 - cell transplantation therapy 416
 - gene replacement therapy 416
 - lung disease 415–16
 - lung transplantation 416
 - orthoptic liver transplantation 415
 - pharmacological 415
 - unfolded protein response signaling pathway 410
 - variants 404
- antiviral agents 35–6
- APC (adenomatous polyposis coli gene) 730
 - acquired mutations 747
- aplastic anemia 46, 500–1
- APOC3 mutations (apolipoprotein C3) 635
- apolipoprotein 94
- apolipoprotein B 14
- arachidonic acid 127, 239–40
- ARC syndrome
 - see arthrogryposis
 - multiplex congenita, renal dysfunction and cholestasis
- arginase deficiency 667
- arginine, urea cycle disorder treatment 670
- argininosuccinate lyase deficiency 667
- Arias syndrome 194
- arthrogryposis multiplex congenita, renal dysfunction and cholestasis (ARC) syndrome 212
- aryl hydrocarbon receptor 15
- ASAH mutations (ceramidase) 553
- ascariasis (*Ascaris lumbricoides*) 684–5, 685f
 - brown pigment gallstones 256
- ascites
 - abdominal paracentesis 60
 - acute liver failure complication 46
 - cirrhosis 54, 60–1
 - imaging 60, 61f
 - onset 60
 - portal hypertension 60, 69, 74
 - renin–angiotensin system 57, 60
 - spontaneous bacterial peritonitis 60–2, 62t
 - treatment 60–1
- asialoglycoprotein receptor antibody, autoimmune hepatitis 312–13
- L-asparaginase 350
- aspartate 12
- aspartate aminotransferase (AST) 10, 90
 - cirrhosis 58
 - liver injury detection 88–9
 - serial measurement 90
- AST:ALT ratio 90
- aspergillosis (*Aspergillus*) 691
- aspirin, drug-induced liver disease 351, 702
- AST, see aspartate aminotransferase
- astrocytes, hepatic encephalopathy 64
- atherosclerosis in cholestasis 122
- atomoxetine 351
- ATP binding cassette (ABC) transporters 24–5
 - Dubin–Johnson syndrome 196
- ATP7B (P-type ATPase) 466–8, 467f
 - function 470
 - mutations 465–7, 470
 - diagnostic molecular genetic testing for Wilson disease 477–8
- ATP8B1 mutations (familial intrahepatic cholestasis 1) 202
- ATP-binding cassette (ABC) transporter 180–2
- autoimmune hemolytic disease 255
- autoimmune hepatitis 311–19
 - animal models 313
 - associated autoimmune disorders 314, 316–17
 - autoantibodies 311–13, 312t
 - cellular immunity 312
 - circulating autoantibodies 311
 - clinical features 314–15, 316t
 - complications 319
 - de novo 319–20
 - diagnosis 313–14
 - differential diagnosis 315–17
 - epidemiology 311
 - evaluation 57
 - genetic predisposition 313
 - hepatocellular carcinoma risk 319
 - histopathology 51f, 314–15, 315f, 316t
 - HLA locus 311, 313
 - humoral immunity 312–13
 - laboratory studies 314, 316t
 - liver transplantation complication 319–20, 781
 - management 317–20
 - budesonide therapy 318
 - calcineurin inhibitors 318
 - immunosuppressive therapy 317–18
 - liver failure treatment 318
 - mycophenolate mofetil therapy 318
 - sclerosing cholangitis overlap syndrome 318
 - treatment failure 319
 - treatment withdrawal 319
 - outcomes 318–19
 - pathogenesis 311–12
 - prognosis 318–19
 - recurrent post-transplant 319–20
 - sclerosing cholangitis overlap 314–15, 316t, 324–6, 326f
 - management 318
 - scoring system 313–14
 - survival 319
 - type 1 311–12
 - type 2 311–13
- autoimmune hepatitis-like hepatotoxicity 344–5
- minocycline-induced 357
- propylthiouracil-induced 359
- autoimmune liver disease 40
 - see also gestational autoimmune liver disease
- serological markers 36
- autoimmune
 - polyendocrinopathy–candidiasis–ectodermal dystrophy syndrome 316
- autoimmune sclerosing cholangitis 322, 326
- autoimmune thyroid disease 705
- autophagosomes, α_1 -antitrypsin deficiency 409
- autophagy enhancer compounds 415
- autosomal dominant polycystic kidney disease 711, 720–2
 - clinical features 721–2
 - congenital hepatic fibrosis association 712, 716
 - diagnosis 721
 - genetics 722
 - management 722
 - pathogenesis 721, 723–5
 - pathology 720f, 720–2
 - treatment 721
- autosomal recessive polycystic kidney disease 711, 716–18
 - clinical features 716–17
 - congenital hepatic fibrosis association 712
 - diagnosis 717
 - esophageal varices 717
 - genetics 717
 - pathogenesis 723–4
 - pathology 717f, 717
 - treatment 717–18
- autotaxin in pruritus 119
- Axenfeld anomaly 224
- azathioprine
 - autoimmune hepatitis treatment 317–20
 - drug-induced liver disease 352
- azithromycin 353
- azotemia 63t
- B-cells 41
- bacterial infections 673–82
 - acalculous cholecystitis 249f, 250
 - brown pigment gallstones 255
 - brucellosis 678
 - cat scratch disease 676–7, 677f
 - cholangitis 675–6, 676f
 - Kasai procedure complication 167, 675
 - sepsis-associated hyperbilirubinemia 673
 - ehrlichiosis 680
 - hydrops of gallbladder 249
 - hyperbilirubinemia with sepsis 673
 - listeriosis 678–9
 - liver transplantation 776–7
 - Lyme disease 681
 - neonatal hepatitis 140–3
 - perihepatitis 676
 - pyogenic liver abscess 673–5
 - streptococcal 250, 678
 - toxic shock syndrome 678
 - tularemia 678
 - typhoid hepatitis 677–8
 - Yersinia enterocolitica* 678
 - see also specific infections and agents
- Baraitser–Reardon syndrome 149–50
- bariatric surgery in non-alcoholic fatty liver disease 646
- Bartonella henselae* 676–7
- Bartter syndrome 249
- basiliximab 382
- BCS1L mutations (respiratory chain complex III) 611
- Beckwith–Wiedemann syndrome 730, 731f, 745
- Behçet syndrome 70, 704
- benign recurrent intrahepatic cholestasis 199
 - ABCB11 mutations (BSEP) 204
 - clinical features 201
 - genetics 202
 - histopathology 201–2
 - laboratory findings 201
- beta-blockers 77–8
- bezafibrates 600
- bile
 - cellular mechanisms of formation during development 19–21
 - cholesterol 256–7
 - constituents 24, 26, 256–7, 257f
 - lipids 257–8
 - transfer into systemic circulation 118–19

Index

- fetal secretion 18
 formation 420, 421*f*
 hepatic transporters in
 formation 25*f*
 milk of calcium 252
 physiology of formation 24
 retention of constituents in
 cholestasis 111–14
 secretion failure 21
- bile acid(s)
 5 α -reduced 570–1
 amidation 571
 anion transporters 20
 atypical 571
 concentration 26
 during development 17–18
 conjugation 571–2
 defects 583*f*
 deconjugation 572
 decreased delivery in
 cholestasis 124
 7 α -dehydroxylation 572
 enterohepatic circulation 17
 flux across hepatocytes 25*f*, 26
 glucuronidation 572
 homeostasis regulation 17–18
 hydrophilic 620–1
 intestinal absorption 18
 intracellular transport 20
 laboratory assessment 96
 metabolism 567, 568*f*
 in fetal/neonatal liver 17–18
 nuclear receptor activation 26
 PFIC1 201
 retention within hepatocytes
 26, 28–9, 29*f*
 secondary 568, 572–3
 serum concentration
 measurement 96
 serum levels in infants 18
 structure 567*f*, 567
 sulfation 571
 toxicity in cystic fibrosis 423
 transport 24–6, 25*f*, 241
 Zellweger syndrome treatment
 658
- bile acid synthesis 26
 acidic pathway 568–9
 amidation genetic defects 571,
 582–3
 cholesterol 7 α -hydroxylase
 569, 572–3
 conjugation 571–2
 defects 115
 in fetal/neonatal liver 17–18
 intestinal bacterial
 modifications 568, 572–3
 metabolic reaction sites 574*f*
 neutral pathway 568
 pathways from cholesterol
 567–72
 in peroxisomes 653
 regulation 572–3
 sterol side-chain metabolic
 reactions 579*f*
- bile acid synthesis disorders 567,
 573–84
 bile acid-CoA conjugation
 defects 582–4
 cholestasis 584*t*, 584
 cholesterol 7 α -hydroxylase
 (CYP7A1) deficiency 575
 diagnosis 573*f*, 573–4
 genetic defects 574*t*
 3 β -hydroxy- Δ^5 -C₂₇-steroid
 oxidoreductase deficiency
 576–8
 2-methylacyl Co-A racemase
 deficiency 580–1
 Δ^4 -3-oxosteroid 5 β -reductase
 (AKR1D1) deficiency
 578–9
 oxysterol 7 α -hydroxylase
 (CYP7B1) deficiency
 575–6
 peroxisomal disorders 581–2
 primary 584
 prognosis 584
 side-chain modification
 reaction defects 579
 side-chain oxidation defect in
 25-hydroxylation
 pathway 581
 steroid nucleus reaction
 defects 574–5
- bile acid-CoA conjugation
 defects 582–4
 clinical features 583
 diagnosis 583
 treatment 583–4
- bile duct
 common bile duct
 spontaneous perforation
 173–4
 development 2
 NOTCH signaling pathway
 in Alagille syndrome
 230
 differentiation in Caroli
 syndrome 718
 drug-induced injury in cells
 344
 epithelial cell drug-induced
 injury 344
 fibrosis in sclerosing
 cholangitis 330
 morphogenesis
 defect in biliary atresia
 157–9
 intrahepatic ducts 159
 obstruction
 brown pigment gallstones
 256
 liver transplantation
 complications 781
 “onion skin” appearance in
 sclerosing cholangitis
 330*f*, 330
 reconstruction following liver
 transplantation 770
- remodeling 1, 158
 solitary benign cyst 739
 strictures
 fever in liver transplantation
 777
 liver transplantation
 complications 781, 782*f*
 see also extrahepatic bile duct;
 intrahepatic bile duct
- bile duct adenocarcinoma 173
 bile duct paucity 6–7, 104
 Alagille syndrome 26, 104,
 218*f*, 218, 225*f*, 226*t*
- bile flow 420
 dynamics 24–6
 fetal 18–19
 impairment detection tests 88,
 90–2
 lipopolysaccharide exposure
 27–8
 obstruction 26
- bile leaks, liver transplantation
 complications 780
- bile pigment
 composition 194*f*
 excretion 181*f*
- bile salt export pump *see* BSEP
- bile salts
 Alagille syndrome levels 217
 metabolism in cystic fibrosis
 258
 serum levels in PFIC3 210–11
- biliary agenesis 156, 165
 biliary atresia 51*f*, 52*f*, 105,
 155–70
 acholic stools 105
 Alagille syndrome differential
 diagnosis 226–7
 anatomic variants 165
 α_1 -antitrypsin deficiency
 differential diagnosis 413
 bile duct obliterative process
 157
 bile flow obstruction 26
 biliary tree patency 109
 clinical features 157
 clinical forms 156–7
 congenital absence of
 gallbladder 247
 cystic variant 156–7
 diagnosis 105, 157, 161–4
 biopsy 162–3
 evaluation 161–2
 imaging 162–4
 prior to surgery 165
 surgical exploration 163–4
 differential diagnosis 108
 idiopathic cholestasis 162
 etiology and pathogenesis
 157–61
 biliary tract morphogenesis
 defect 157–9
 continuum of disease 161*f*
 environmental toxin
 exposure 160
- genetics 158–9
 immunologic mechanism
 disorders 160
 pro-inflammatory
 mechanisms 160
 vascular abnormalities 160–1
 viral infections 157–8
 evaluation of infants with
 cholestasis 161*t*
 extrahepatic 155
 extrahepatic anomalies 156*t*
 fetal form 156
 histopathology 163*f*
 imaging 107–8
 incidence 156
 inflammatory process 156
 intrahepatic cholestasis
 differentiation 162
 intrahepatic ductal injury 155
 management 164–7, 170*f*
 liver transplantation 155–6,
 168–70, 761
 medical treatment following
 surgery 168
 sequential approach 169–70
 surgical 164–8, 166*f*
 see also Kasai procedure
 neonatal hepatitis differential
 diagnosis 150
 neonatal sclerosing cholangitis
 325
 peri-/postnatal form 156
 portal hypertension 70, 75
 prognosis 167
 reovirus 3 infection 148
 screening 157
 stages 159*f*
 survival rate 170
 ursodeoxycholic acid therapy
 115
 variceal hemorrhage 75
see also cholestasis
- biliary atresia splenic
 malformation syndrome
 156
- biliary cirrhosis 51*f*, 51–2, 52*f*
 focal in cystic fibrosis 427
see also primary biliary
 cirrhosis
- biliary colic 251–2
 gallstones 259–60
- biliary epithelial cells
 primary sclerosing cholangitis
 333
 purinergic (P₂) receptors 421
- biliary epithelium
 mechanosensitive pathways
 421
 secretion mechanism 420
- biliary ischemia 781
- biliary microhamartomas 721–2
- biliary phospholipid 208–9
- biliary sludge
 black pigment gallstones 256
 TPN-associated 255

Index

- biliary sludge (cont.)
 intestinal failure-associated
 liver disease 235, 238
biliary stasis 238
biliary tract disease
 in cystic fibrosis 428
 genetic predisposition in
 primary sclerosing
 cholangitis 332–3
 in portal hypertension 70–1
biliary tree
 congenital dilatation 718
 embryologic development 710
bilirubin
 Alagille syndrome levels
 217–18
 albumin carrier molecule 178
 antioxidant capacity 177
 conjugated 94–5
 delta form 94–5, 182
 export of conjugated 25–6
 fraction determination 182–4
 jaundice assessment 182–4
 laboratory assessment 94–5
 measurement 182
 reduction and oxidation to
 urobilinoids 183f
 solubility 177–8
 spectrophotometry 95
 structure 177–8
 unconjugated 94–5
 black pigment gallstones
 255
 Gilbert syndrome 190
 pigment gallstones 255
 bilirubin-binding agents 195
 bilirubin diglucuronide 180f
 bilirubin encephalopathy 188
 bilirubin metabolism 177–82,
 179f
 circulation 177–8
 conjugation 180
 enterohepatic circulation 182,
 186–7
 excretion of bilirubin
 conjugates 180–2
 formation 177
 hepatocyte uptake 178–80
 production 177–8
 see also jaundice; neonatal
 jaundice
 bilirubin metabolism disorders
 190
 Rotor syndrome 195–6
 see also Crigler–Najjar
 syndrome;
 Dubin–Johnson
 syndrome; Gilbert
 syndrome; neonatal
 jaundice
 bilirubin UDP
 glucuronosyltransferase
 Gilbert syndrome 191
 induction by phenobarbital
 190
 biologic therapies 702
 biopsy
 acute liver failure 35, 43f
 biliary atresia diagnosis 162–3
 cirrhosis 57
 cystic fibrosis 429
 erythropoietic protoporphyria
 522f
 fucosidosis 557
 Gaucher disease 549
 hereditary hemochromatosis
 498
 HIV infection 149
 iron overload 499
 neonatal cholestasis 108–9
 neonatal hepatitis 141f
 Niemann–Pick disease type C
 555
 non-alcoholic fatty liver
 disease 640
 secondary iron overload 502
 Wilson disease 477, 481
 biotransformation 341–4
 abnormal 345
 N-acetyltransferase 2 16
 aryl hydrocarbon receptor 15
 constitutive androstane
 receptor 15
 CYP450 isozymes 15–16
 developmental changes
 14–15t
 epoxyhydroxylase 17
 in fetus and neonate 14–17
 flavin-containing
 monooxygenases 16
 glutathione S-transferases 16
 nuclear receptors 15
 pregnane X receptor 15
 stages of 14
 phase I 14–15, 17
 phase II 14, 16–17
 phase III 14, 17
 sulfotransferases 16–17
 UDP-glucuronosyltransferases
 16
 variable influencing 14
 see also drug metabolism
 blood supply to liver 695
 blood transfusions
 hemosiderosis 698
 HAV acquisition 145
 neonatal hemochromatosis
 treatment 506, 762–3
 neonatal jaundice 190
 post-transfusion hepatitis 147
 Rhesus incompatibility 186
 secondary iron overload 500–2
 boceprevir 307
 body composition in cholestasis
 124–6
 bone marrow transplantation
 acid sphingomyelinase
 deficiency 553
 Farber disease 553
 mucopolysaccharidoses 562
 bone mineral density in
 cholestasis 126
 bone morphogenetic proteins 2
 borreliosis (*Borrelia*) 681
 brainstem auditory-evoked
 potentials 188
 branched-chain amino acids
 126–7
 breast-feeding
 β-glucuronidase levels 182
 with HBV infection 280–1
 neonatal jaundice association
 187, 190
 bromosulphophthalein,
 hepatocellular transport
 18, 59
 brucellosis (*Brucella*) 678
 BSEP (bile salt export pump)
 20–1, 25f, 25, 204, 241
 ABCB11 mutations 204
 benign recurrent intrahepatic
 cholestasis 204
 defect in 115
 PFIC2 205–6
 Budd–Chiari syndrome 70,
 696–8
 acute 697
 classification 696
 clinical presentation 697
 estrogen-induced 353
 imaging 697
 primary 696
 risk factors 696–7
 secondary 696
 treatment 697–8
 budesonide, autoimmune
 hepatitis management
 318
 Byler’s disease see progressive
 familial intrahepatic
 cholestasis type 1
 caffeine
 cirrhosis evaluation 59
 metabolism rate in children
 343
 calcineurin inhibitors
 autoimmune hepatitis
 management 318–20
 liver transplantation 774–5
 dose reduction 775
 side effects 784
 calcitriol 130
 calcium 134–5, 137
 calcium carbonate 255
 calcium phosphate
 Crigler–Najjar syndrome
 treatment 195
 pigment gallstones 255
 Campath-1H in stem cell
 transplantation 382
 canalicular multispecific organic
 anion transporter 180–1,
 196
 Candida infection 688–9
 capillariasis (*Capillaria hepatica*)
 685
 CAR see constitutive androstane
 receptor
 carbamazepine
 α₁-antitrypsin deficiency
 treatment 415
 drug-induced liver disease
 352
 carbamoylphosphate synthetase
 deficiency 396
 carbohydrate metabolism
 fetal and neonate liver 11–12
 inborn errors 435–58
 fructose metabolism
 442–7
 galactose metabolism
 435–42
 glycogen storage diseases
 447–58
 carcinogenesis, peroxisome
 proliferator-induced 651
 cardiac cirrhosis 51–2
 cardiac disorders
 congenital 696
 hepatic dysfunction 695–6
 tyrosinemia pathology 537
 Wilson disease 474–5
 cardiac output in portal
 hypertension 71–2
 cardiogenic mesoderm 1f, 2–3
 cardiovascular anomalies in
 Alagille syndrome 219t,
 219–20
 cardiovascular development,
 NOTCH signaling
 pathway 230–1
 cardiovascular shock 38
 carmustine 350
 carnitine 592
 fatty acid oxidation disorders
 395, 592–3
 parenteral nutrition
 component 239
 serum levels in valproic acid
 hepatotoxicity 362
 shuttle defects 592–3
 supplementation
 in fatty acid oxidation
 disorders 598–9
 in long-chain fatty acid
 oxidation disorders 593,
 599
 in medium chain acyl-CoA
 dehydrogenase deficiency
 599
 carnitine palmitoyltransferase I
 587–9
 carnitine palmitoyltransferase IA
 deficiency 592–3
 carnitine palmitoyltransferase II
 deficiency 592–3
 carnitine transport defects 592
 carnitine transporter (*OCTN2*)
 592–3

Index

- carnitine:acylcarnitine translocase 589
deficiency 592–3
- Caroli disease 716, 718–20
with choledochal cysts 173
clinical features 718
differential diagnosis 718
pathology 718
treatment 718–20
- Caroli syndrome 718–20
clinical features 718
differential diagnosis 718
imaging 719*f*
pathology 718*f*, 718
treatment 718–20
von Meyenburg complexes 721
- castanospermine 415
- cat scratch disease 676–7
- catalase 655
- cataracts
galactokinase deficiency
galactosemia 441
sunflower in Wilson disease 472
transferase deficiency
galactosemia 437–9
- β -catenin 3
- catheter-associated infections 241
- CD8 cells 41
- CD40 ligand deficiency 374*f*, 374
- CD44 348–9
- ceftriaxone 256
- celiac disease 38, 705
- central nervous system
acute liver failure
complications 44–6
cirrhosis complications 56
- cerebral edema 45–6
- cerebrotendinous xanthomatosis 579–80
- cerebrovascular abnormalities in Alagille syndrome 220–1
- cerulide 620
- ceruloplasmin 467, 470
- chenodeoxycholic acid 568
7 α -dehydroxylation 572
gallstone dissolution 261–2
peroxisomal disorder
treatment 661
serum concentrations of
conjugates in neonates 18*f*
synthesis 568*f*, 569
- chloride ion channels 419–20
bile formation 421*f*
biliary epithelium secretion
mechanism 420
cystic fibrosis 432
- cholangiocarcinoma
Alagille syndrome association 730
congenital hepatic fibrosis
association 715
pathology 739
primary sclerosing cholangitis
complication 337
PFIC2 204
von Meyenburg complex
association 721
- cholangiocytes 1–2
bile flow 26
chloride ion channels 420–1
cilium defects 7
differentiation control by
transcription factors 4*t*, 6
extrahepatic bile duct 7
hepatoblast differentiation into 2*f*, 5–6
injury in PFIC3 210
polarity 7
- cholangiopathy, malignancy
association 374
- cholangitis
bacterial 675–6, 676*f*
Kasai procedure
complication 167, 675
sepsis-associated
hyperbilirubinemia 673
congenital hepatic fibrosis 715–16
cryptococcosis infection 689–90
obliterative in PFIC3 210
oriental 685*f*
recurrent 115
sepsis-associated
hyperbilirubinemia 673
- cholecystectomy 261–2, 428
- cholecystitis
acalculous 249*f*, 250–1
chronic 261
treatment 261–2, 428
- cholecystokinin
cholestasis therapy 116–17
secretion in intestinal failure-associated liver disease 238
- cholecystokinin-octapeptide 243
- choledochal cysts 155, 170–3
classification 171*f*
clinical features 171
complications 173
diagnosis 172
frequency 170
imaging 172*f*, 172–3
malignancy in 173
management 172–3, 173*f*, 174*f*
outcome 173
pathogenesis 171–2
spontaneous perforation 171
subtypes 170, 171*t*
- cholelithiasis
associated conditions 254*t*
in cystic fibrosis 428
inflammation 261
intestinal failure-associated
liver disease 235, 238
low phospholipid-associated
syndrome 208
treatment 261–2
see also gallstones
- choleretic agents 113–14
see also chenodeoxycholic acid; ursodeoxycholic acid
- cholestanoic acids 570
- cholestasis 24, 101–9
acquired mechanisms 27–8
adaptation to 25*f*, 28–9
adolescents 137
Alagille syndrome 217, 219, 227
ARC syndrome 212
atherosclerosis 122
bile acid decreased delivery 124
bile acid synthesis disorders 584*t*, 584
bile constituents retention 111–14
bile duct paucity 104
bilirubin levels 95
black pigment gallstones 256
body composition 124–6
bone mineral density 126
causes 112*t*
cholecystokinin therapy 116–17
classification of disorders 102*t*
cognitive impairment 136–7
cognitive outcomes 124
complications 111
definition 26, 101
dental hygiene 137
detection tests 88, 90–2
diagnosis 111
drug-induced 28
estrogen-induced 353
extrahepatic 101
family support 137–8
fatigue 122
genetic mechanisms 27
glucocorticoid therapy 116
growth failure 136–7
growth hormone levels 124
hepatic osteodystrophy 126
hepatocellular injury 111–13
hereditary with lymphedema 211–12
hyperlipidemia 122–3
immunizations 137
incidence 101–2
intestinal failure-associated
liver disease 234–6
intrahepatic 101
of pregnancy 204
liver dysfunction in neonate 21
liver transplantation 111, 761
malabsorption 123–4
management 111–38, 113*t*
neonatal
biliary tree patency 109
cystic fibrosis presentation 426
diagnosis 106–7, 109
differential diagnosis 102–4
evaluation 104–9, 106*f*, 107*t*
hyperbilirubinemia 104, 150
imaging 107–8
inherited 104
jaundice 102
management 111
manifestations 104–6
ABCB4 mutation (MDR3) 208
symptoms 105–6
- neonatal hepatitis 140
- neonatal sclerosing cholangitis 325
- North American Indian 212–13
- nor*-ursodeoxycholate therapy 116
- nuclear receptor(s) 26–7
nuclear receptor agonist
therapy 117, 432
- nutritional assessment 124–6
- nutritional therapy 125*t*, 126–36
aluminum 136
calcium 134–5, 137
copper 136
energy 126
essential fatty acids 127
fat 124*f*, 126
fat-soluble vitamins 124*f*, 127–34
iron 136
magnesium 135
manganese 136
phosphate 134–5, 137
protein 126–7
selenium 135
vitamin A 127–30, 128*f*, 129*t*
vitamin D 130*f*, 130–1, 131*f*, 137
vitamin E 131–4, 132*f*
vitamin K 134
water-soluble vitamins 134
zinc 135
- pathogenesis 111–13
pediatric care 136–8
phenobarbital therapy 116
physiologic of infancy 18
principles 26–7
prognosis 111
sepsis-associated 27–8, 238, 695
sickle cell intrahepatic 698
spontaneously resolving 104
tauroursodeoxycholic acid
therapy 116
TPN-associated 28, 115, 234, 239
ursodeoxycholic acid therapy 113–16

Index

- cholestasis (cont.)
 - vitamins, fat-soluble 127–34
 - xanthomas 122–3
 - see also benign recurrent intrahepatic cholestasis
- cholesterol 13
 - Alagille syndrome levels 217–18
 - bile acid synthesis pathways 567–72
 - biosynthesis 654
 - crystal formation in bile 257
 - glycogen storage disease type IA 450–1
 - maternal 13
 - solubility in bile 257
 - supersaturation of bile 256–7
 - see also gallstones, cholesterol
- cholesterol 7 α -hydroxylase (CYP7A1) 569, 572–3
- deficiency 575
- cholesterol synthesis-blocking agents 123
- cholesterolemia of gallbladder 252
- cholesteryl ester storage disease 561
- cholestyramine 119–20, 195
- cholic acid 568
 - 7 α -dehydroxylation 572
 - peroxisomal disorder
 - treatment 661
 - serum concentrations
 - conjugates in neonates 18f
 - cystic fibrosis 430
 - synthesis 568f, 569
- choline, parenteral nutrition component 239
- chromium toxicity 241
- chromosomal abnormalities/disorders
 - liver tumors 752
 - neonatal hepatitis 149
- chronic granulomatous disease 381
- chronic liver disease
 - amenorrhea in adolescents 137
 - dental hygiene 137
 - diagnostic tests 58t
 - family support 137–8
 - growth and development 136–7
 - immunizations 137
 - immunologic disturbance 371
 - malnutrition 65–6
 - pediatric care 136–8
 - serum albumin levels 92–3
 - tyrosinemia 530, 540–1
 - see also cirrhosis
- cigarette smoking, α_1 -antitrypsin deficiency 402, 414
- circulatory failure, hepatic dysfunction 695–6
- cirrhin 213
- cirrhosis 51–66
 - Alagille syndrome 219f, 219
 - albumin levels 58
 - ammonia levels 97
 - anemia 55
 - ascites 54, 60–1
 - associated diseases 52t
 - AST:ALT ratio 90
 - biliary scintiscan 57
 - biopsy 57
 - black pigment gallstones 256
 - classification 51–2
 - clinical features 54, 55t
 - clinical outcomes 52
 - clotting factors 58–9
 - coagulopathy 55–6, 59–60
 - compensated 52, 54
 - complications 55–7
 - cardiovascular 56
 - endocrinological 56
 - hematologic 55–6
 - immunologic 57
 - management 59–63
 - neurologic 56
 - nutritional 57
 - orthopedic 57
 - pulmonary 54–5
 - renal 57
 - cyanosis 54
 - in cystic fibrosis 427f, 427, 430–1
 - decompensated 52, 54
 - definition 51
 - diagnostic tests 58t
 - digital clubbing 54
 - diuretic use 61
 - dynamic tests 59
 - endoscopic retrograde cholangiopancreatography 57
 - evaluation 57–9
 - extracellular matrix 52–3
 - fibrinolysis 60
 - fibrogenesis 52–3
 - focal biliary 427f, 427, 430–1
 - hepatic encephalopathy 54, 64–5
 - hepatic osteodystrophy 57
 - hepatocellular 51–2
 - hepatocellular carcinoma
 - predisposition 54
 - hepatopulmonary syndrome 54–5
 - hepatorenal syndrome 62t, 62–3
 - histologic patterns 51–2
 - hyperbilirubinemia 58
 - idiopathic copper toxicosis 490
 - Indian childhood cirrhosis 487–8
 - infections 57
 - laboratory tests 57
 - liver function assessment 58–9
 - liver transplant 59
 - malnutrition 57, 65–6
 - manganese levels in globus pallidus 136
 - multilobular 427f, 427, 430–1
 - pathophysiology 52–4
 - platelet effects 60
 - regeneration of liver 54
 - sickle cell disease 698
 - skin changes 54
 - sodium excretion promotion 61
 - staging systems 51
 - tyrosinemia 533–5, 540–1
 - ultrasonography 57
 - venous anastomoses 97
 - Wilson disease 472–3, 479, 481
 - see also biliary cirrhosis; primary biliary cirrhosis
- cirrhosis-associated immune dysfunction syndrome 57
- cirrhotic cardiomyopathy 72
- cis-platinum 350
- citrin deficiency (citrullinemia II) 667
- clarithromycin 353
- Clonorchis sinensis* (liver fluke) 687f, 687
- clotting factors
 - in cirrhosis 58–9
 - factor V Leiden mutations 697
 - factor VIII 93
 - laboratory assessment 88
- coagulation disorders/coagulopathy 698
 - acute liver failure 42, 46
 - of cirrhosis 55–6, 59–60
 - laboratory assessment 59–60, 93–4
 - portal hypertension 70
- cocaine 352
- coccidioidomycosis (*Coccidioides immitis*) 689, 690f
- coenzyme A esters 570, 651
- coenzyme Q 624–5
- cognitive impairment
 - Alagille syndrome 225–6
 - cholestasis 124, 136–7
 - hypertyrosinemia 539
 - liver transplantation 785
 - medium chain acyl-CoA dehydrogenase deficiency 595
- PFIC1 200
- transferase deficiency
 - galactosemia 441
- colchicine 117–18
- colesevelam hydrochloride 119–20
- colestipol 119–20
- collagen 53
- collagen vascular disease 702–4
- combined immunodeficiency 373f
- common variable immunodeficiency 375
- complementary and alternative medicines 36, 354–5
- computed tomography see CT
- congenital bile duct cysts 170, 171f
- congenital disorders of glycosylation 706–7, 707t
- congenital erythropoietic porphyria 509, 513, 521
- clinical features 521
- diagnosis 521
- hepatoerythropoietic porphyria differential diagnosis 519
- treatment 521
- congenital heart disease 696
- congenital hepatic fibrosis 712–16
 - autosomal-dominant polycystic kidney disease association 712
 - autosomal-recessive polycystic kidney disease association 712
- cholangitic 715
- clinical manifestations 714–15, 715t
- cystic disease of pancreas
 - association 712–14
 - diagnosis 715
 - differential diagnosis 716
 - genetic counseling 716
 - imaging 715–16
 - laboratory findings 715
 - liver transplantation 716
 - pathology 714f, 714
 - physical examination 715
 - portal hypertensive 715–16
 - surveillance 716
 - treatment 716
 - von Meyenburg complexes 721
- congenital hypothyroidism 187
- congenital spherocytosis 255
- congenital syphilis 142
- congestive hepatopathy in cystic fibrosis 425–6
- constitutive androstane receptor (CAR) 15, 26, 117
- Coombs-positive giant cell hepatitis 150
- copper
 - absorption 465–8
 - avoidance in parenteral nutrition 242
 - balance in humans 465f
 - in cholestasis 136
 - dietary intake 465–6
 - endogenous detoxification mechanisms 468
 - excretion 467–8
 - free 467
 - hepatocyte metabolism 466f
 - intestinal failure-associated liver disease 241
 - metabolism 465–8

Index

- metallochaperone role 467
- organ distribution 468
- oxidative injury 468–9
- toxicity mechanisms 468–9
- transport 466
- see also idiopathic copper
- toxicosis; Indian
- childhood cirrhosis;
- Wilson disease
- copper chelation therapy
- idiopathic copper toxicosis 491
- Indian childhood cirrhosis
- 488–9
- Wilson disease 465, 473,
- 483–5, 619
- coproporphyrin
- congenital erythropoietic
- porphyria 521
- harderoporphyria 520
- hereditary coproporphyria 519
- levels in variegate porphyria
- 520
- urinary excretion 196
- corticosteroids
- autoimmune hepatitis
- treatment 317–20
- drug-induced liver disease
- treatment 362
- cortisol, fetal circulation 10
- cortisone, fetal circulation 10
- Coxiella burnetti* 682
- coxsackievirus 147–8
- creatine deficiency 671
- Crigler–Najjar syndrome 191*t*,
- 193–5
- bile pigment composition 194*f*
- clinical presentation 193–4
- diagnosis 194–5
- gene therapy 195
- management 195
- pathophysiology 194
- types 193–4
- UGT1A* mutations (UDP-
- glucuronosyltransferase)
- 16, 180, 194
- unconjugated
- hyperbilirubinemia 95
- Crohn disease
- gallbladder inflammatory
- lesions 252
- ileal 258
- sclerosing cholangitis
- association 326–7
- crotonase 591
- Cruveilhier–Baumgarten
- syndrome 73
- cryptococcosis (*Cryptococcus*
- neoformans*) 689–90
- cryptosporidiosis
- (*Cryptosporidium*) 373*f*
- HIV opportunistic infection
- 376–7
- management in
- immunodeficient patients
- 375
- sclerosing cholangitis
- development 373–4
- Cryptosporidium parvum* 373–5
- CT (computed tomography)
- cystic fibrosis 429
- neonatal cholestasis 108
- Wilson disease diagnosis 480
- CTFR (cystic fibrosis
- transmembrane receptor)
- 419–20
- and bile flow 26
- chloride ion channels 419–20,
- 421*f*
- correctors 432
- functions 419
- liver disease in cystic fibrosis
- 422
- liver function role 420
- potentiators 432
- regulator role 419–20
- structure 420*f*
- CFTR* mutations 421–2
- classification 422*f*, 422
- in primary sclerosing
- cholangitis 334
- CTNNB1* mutations (β-catenin)
- 747–8
- Cushing syndrome 704, 733, 739,
- 745*f*
- cyanosis in cirrhosis 54
- cyclooxygenase inhibitors 358
- cyclophosphamide 35–6, 350
- cyclosporine
- autoimmune hepatitis
- management 318
- drug-induced liver disease 352
- cystathionase 13
- cysteine 13
- cystic fibrosis 419–33
- α₁-antitrypsin role 424
- bile salt metabolism 258
- biochemical evaluation 428,
- 429*f*
- biomarkers 430
- biopsy 429
- carrier frequency 421
- chloride ion channels 424, 432
- cholesterol gallstone formation
- 258–9
- clinical presentation of liver
- injury 425, 426*t*
- biliary tract disease 428
- cholelithiasis 428
- cirrhosis 427*f*, 427, 430–1
- congestive hepatopathy
- 425–6
- hepatomegaly 425–6, 428
- neonatal cholestasis 426
- steatosis 426*f*, 426–7
- diagnosis 428, 429*f*
- gallbladder hypoplasia 247–8
- historical aspects 419
- human leukocyte antigens
- 424
- imaging 428–9
- incidence 421
- meconium ileus history 424
- nutritional assessment 428
- nutritional management 430–1
- pathogenesis of liver injury
- abnormal *CFTR* protein 422
- antioxidants 423
- α₁-antitrypsin role 424
- bile duct plugging theory
- 422
- chloride ion channels 424
- cirrhosis 422–3
- fibrogenesis 422–3
- genetic modifiers 424–5
- hepatic steatosis 424
- immune status 424
- model for 423*f*
- mucin secretion 423
- pathogenesis 422–3
- stellate cells 423–4
- toxic bile acids 423
- physical examination 428
- portal hypertension
- management 431
- prevalence of liver injury 425
- screening 428
- steatosis 426*f*, 426–7, 430
- treatment 430–2
- alternate chloride channel
- strategies 432
- antifibrotic agents 432
- antioxidants 432
- CFTR* correctors/
- potentiators 432
- future therapies 431–2
- gene therapy 432
- liver transplantation 431,
- 764
- nutritional rehabilitation
- 430–1
- portal hypertension
- management 431
- steatosis 430
- ursodeoxycholic acid
- therapy 114–15, 430–2
- cystic fibrosis transmembrane
- receptor see *CFTR*
- cytochrome *c* oxidase deficiency
- 611
- cytochrome P450 (*CYP450*) 342,
- 509–10
- biotransformation 15–16
- classification 342
- CYP1A1* subfamily 15
- CYP1A2* subfamily 15
- CYP2C* subfamily 15–16
- CYP2D6* subfamily 16
- CYP2E1* subfamily 16
- CYP3A* subfamily 16
- development 15*f*
- neonates 343
- polymorphisms 342
- cytokines
- immunologic disturbance 371
- proinflammatory 695
- cytomegalovirus
- in biliary atresia 157
- congenital 143–4
- diagnosis 143
- HIV opportunistic infection
- 376
- liver transplantation
- febrile patient evaluation
- 777
- risk 773, 776–7
- treatment 777
- neonatal hepatitis 143*f*,
- 143–4
- treatment 143–4
- dacarbazine 35–6
- daclizumab 382
- dactinomycin 350
- danazol 415
- D-bifunctional protein 651,
- 658–9
- deficiency 652–3, 656
- deferasirox 501
- deferiprone 501
- deferoxamine 501*f*, 501
- dehydrogenase 10
- delta hepatitis see hepatitis D
- virus
- delta-bilirubin 94–5, 182
- dental hygiene in cholestasis 137
- deoxycholic acid 572
- deoxyguanosine kinase 763
- DGUOK* mutations 613, 763
- deoxymannojuronicin 415
- dermatomyositis 704
- development see functional
- development of liver;
- liver development
- developmental delay
- see cognitive impairment
- diabetes mellitus 705
- calcineurin inhibitor toxicity
- 784
- infants of diabetic mothers and
- neonatal jaundice 187
- type 1 252
- diclofenac 357–8
- diet
- copper intake 465–6
- glycogen storage disease
- type IA 454
- type III 456
- type IV 458
- hyperlipidemia treatment 123
- mitochondrial hepatopathies
- treatment 626
- in non-alcoholic fatty liver
- disease 643–5
- dietary supplements 706
- digital clubbing
- cirrhosis 54
- hepatopulmonary syndrome
- 55
- direct acting antiviral drugs
- 307–8

Index

- divalent metal transporter 1 493–4
- docosahexaenoic acid 653
 - deficiency 599–600
 - peroxisomal disorder treatment 661
- donor risk index for liver transplantation 767–8
- double glucagon tolerance test 456
- Down syndrome 149
 - gallbladder motility impairment 252
 - neonatal hemochromatosis association 502–3
- D-penicillamine 136
 - fibrosis treatment 118
 - Indian childhood cirrhosis 489
 - side effects 484
 - Wilson disease management 483–4, 486–7
- drug abuse
 - HAV association 267
 - HCV association 297
- drug hypersensitivity syndrome 344
- drug metabolism 341–4
 - developmental changes 343
 - hepatocellular mitochondria role 343
 - phase I reactions 341–3
 - phase II reactions 341–4
 - stages of 14
 - see also biotrans-formation; cytochrome P450
- drug-induced liver disease 34*t*, 341–62
 - acetaminophen 34–5, 41, 347–9
 - amiodarone 350
 - antineoplastic drugs 350–1
 - aspirin 351
 - atomoxetine 351
 - azathioprine 352
 - carbamazepine 352
 - cholestasis 28
 - clinical presentation 344, 345*t*, 347*t*
 - cocaine 352
 - complementary and alternative medicines 36, 354–5
 - cyclosporine 352
 - diagnosis 362
 - drug hypersensitivity syndrome 344
 - Ecstasy 352–3
 - erythromycin 353
 - estrogens 353
 - felbamate 353–4
 - haloperidol 354
 - halothane 354
 - hepatic drug metabolism 341–4
 - hepatocellular damage amplification 345–6
 - hepatotoxins 344–62
 - classification 344–6
 - herbal medications 354–5
 - idiosyncratic drug reactions 35
 - immune response 42
 - infliximab 355
 - isoniazid 355–6
 - ketoconazole 356
 - lamotrigine 356
 - liver transplantation 362
 - 6-mercaptopurine 352
 - methotrexate 356–7
 - minocycline 357
 - mitochondrial injury 41
 - neonatal jaundice 187
 - nevirapine 357
 - non-steroidal anti-inflammatory drugs 357–8
 - oral contraceptives 353
 - pathology 43*f*, 347*t*
 - patterns 344–7
 - pemoline 358
 - penicillins 358
 - phenobarbital 358
 - phenytoin 358–9
 - predictability 345
 - propylthiouracil 359
 - recreational drugs 35–6
 - retinoids 359
 - risperidone 359
 - sulfonamides 359–60
 - systemic syndrome association 344–5
 - treatment 362
 - valproic acid 360–2
- Dubin–Johnson syndrome 25–6, 192*t*, 196
 - clinical features 196
 - diagnosis 196
 - liver discoloration 196
 - pathophysiology 196
 - treatment 196
- ductal plate 5, 710
 - formation 2*f*, 4*t*, 5–6
 - intrahepatic bile duct formation 6
 - remodeling 710, 711*f*
 - arrest in Caroli disease 718
- ductal plate malformations 2, 6–7, 155, 710
- dyskinesia in Wilson disease 474
- eating disorders 705
- echinococcal disease (*Echinococcus granulosus*) 684
- echovirus 147–8
- Ecstasy 352–3
- ectoderm 1–2
- ehrlichiosis 680
- electron transfer flavoprotein 595
- electron transport deficiency 617–18
- eliglustat tartrate 551
- embryonal rhabdomyosarcoma 252
- encephalopathy see hepatic encephalopathy
- endemic Tyrolean infantile cirrhosis see idiopathic copper toxicosis
- endoderm 1–2
- endoplasmic reticulum 635
- endoscopic retrograde cholangiopancreatography 108
- endothelin-1
 - hepatopulmonary syndrome 73
 - portal hypertension 71
- endotoxin 27–8
- energy requirements in cholestasis 126
- 2-enoyl CoA hydratase 590–1
- Entamoeba histolytica* infection 674, 682–4
 - clinical manifestations 683*f*, 683
 - diagnosis 683
 - laboratory tests 683
 - mortality 684
 - treatment 683–4
- entecavir 288
- enteroviral hepatitis, neonatal 147–8
- enzyme(s) see also respiratory chain complex enzymes
 - amino acid metabolism 12
 - fatty acid oxidation pathway 588*t*
 - functional development of liver 10–11
 - inherited deficiencies 88
 - urea cycle 665
- enzyme replacement therapy
 - acid sphingomyelinase deficiency 553
 - Gaucher disease treatment 551
 - glycogen storage disease type II 560
 - mucopolysaccharidoses treatment 562–3
 - pancreatic 431
- epidermal growth factor 723
- NOTCH signaling pathway 229
- epidophyllotoxin etoposide 380
- epimerase deficiency
 - galactosemia 435, 441–2
- epithelial differentiation stage 2
- epithelioid
 - hemangioendotheliomas 740–1, 752
- epoxyhydroxylase 17
- Epstein–Barr virus
 - liver transplantation
 - febrile patient evaluation 777
 - infection risk 170
 - risk 773, 777
 - X-linked proliferative disease association 381
- erythrocytes, erythropoietic protoporphyria 522
- erythromycin 353
- erythropoiesis, ineffective 177
- erythropoietic protoporphyria 513, 521–3
 - biopsy 522*f*
 - clinical features 521–2
 - diagnosis 522
 - liver transplantation 523
 - treatment 522–3
 - X-linked 513
- Escherichia coli*
 - acalculous cholecystitis 250
 - neonatal hepatitis 142
 - sepsis in transferase deficiency galactosemia 437
- esophageal variceal hemorrhage 168
- essential fatty acids
 - in cholestasis 127
 - deficiency in Alagille syndrome 228
 - in fatty acid oxidation disorders 599–600
- estrogens, drug-induced liver disease 353
- ethanol 620
- ether lipid biosynthesis 654
- etretinate 359
- extracellular matrix
 - cirrhosis 52–3
 - fibrosis role 117
 - proteins in fibrogenesis 53
- extracorporeal shock wave lithotripsy 261–2
- extrahepatic bile duct 7
- factor V Leiden mutations 697
- factor VIII 93
- FAH* mutations (fumarylacetoacetate hydrolase) 526–8
- familial adenomatous polyposis 730
- familial hypercholanemia 213
- familial hypobetalipoproteinemia 259
- familial intrahepatic cholestatic syndromes 149
- FIC1* mutations, see progressive familial intrahepatic cholestasis, type 1, genetics
- family support in cholestasis 137–8
- Fanconi syndrome 475
- Fanconi-like syndrome 446
- Farber disease 553

Index

- farnesoid X receptor (FXR)
17–18, 21
activation by bile acids 26
bile acid transport 241
bile salt transport regulation
21, 117
in PFIC1 203*f*
in PFIC3 211
FAS expression in
hepatoblastoma 751
Fasciola hepatica (liver fluke)
687–8
fat oxidation 14
fat requirements in cholestasis
124*f*, 126
fatty acid(s) 13–14
see also essential fatty
acids
plasma concentrations after
birth 14
fatty acid oxidation 14, 587–92
acyl-CoA dehydrogenases
589–90
chain-length specificity 589
dietary composition 587–8
2-enoyl CoA hydratase
590–1
exercise impact 588
fasting state 587
3-ketoacyl CoA thiolases 591
long-chain 606
mitochondrial 589*f*
odd-chain 591–2, 592*f*
pathway 588*t*, 588
peroxisomal 651–3
reaction 590*f*
regulation 587–8
unsaturated fatty acids 592,
593*f*
fatty acid oxidation disorders
387*t*
autopsy screening 397*f*
diagnosis 596
docosahexaenoic acid
deficiency 599–600
fasting avoidance 596–8
inborn errors 587, 592–600
carnitine shuttle defects 395,
592–3
clinical presentation 587
incidence 587
laboratory testing 393–6, 394*t*,
395*f*
long-chain 593–4
medium chain 594–5, 598–9
metabolic abnormalities 597
mitochondrial hepatopathies
617–18
newborn screening 397–8
pregnancy 600
screening 596
short-chain 595
sudden infant death 594, 596
treatment 596–600
acute management 598
bezafibrates 600
carnitine supplementation
598–9
dietary fat restriction 599
essential fatty acids 599–600
night-time hypoglycemia
prevention 598
triheptanoate 600
vitamin B supplementation
600
urea cycle disorder differential
diagnosis 668
vitamin deficiencies 600
fatty acid salts 255
fatty acid synthase 14
felbamate, drug-induced liver
disease 353–4
Felty syndrome 703
ferritin, secondary iron overload
501
ferrochelatase 511
erythropoietic protoporphyria
521–2
ferroportin 493–4, 503
iron absorption role 495*f*
fetal hematopoiesis 10
fever, recurrent in glycogen
storage disease type IA
452
fibrinogen 93
fibrinolysis in cirrhosis 60
fibroblast(s) 1–2
fibroblast growth factor 2, 6
fibrocystic liver disease 710–25
see also autosomal
dominant polycystic
kidney disease; autosomal
recessive polycystic
kidney disease
animal models 723–5, 724*f*
Caroli disease/syndrome
720–1
congenital hepatic fibrosis
712–16, 714*f*, 715*t*
kidney cystic disorders
710–11, 711*t*
pathogenesis 723*t*, 723–5
polycystic liver disease 721–2
solitary non-parasitic cyst 711,
712*f*
syndromes 711*t*
von Meyenburg complexes
721–2
fibrolamellar carcinoma 744*f*
fibrosis *see also* congenital
hepatic fibrosis
in cirrhosis 52–3
congenital 714*f*
extracellular matrix role 117
Gaucher disease 550
glycogen storage disease type
III 456
hepatic congestion 696
hereditary hemochromatosis
497
Indian childhood cirrhosis
488*f*, 488
intestinal failure-associated
liver disease 236
methotrexate-induced 356
myofibroblasts 53
non-alcoholic fatty liver
disease 633
pathogenesis 117
stellate cells role 118
TGF β role 53
treatment 117–18
FIC1 mutations, *see* progressive
familial intrahepatic
cholestasis, type 1,
genetics
flavin-containing
monooxygenases 16
focal nodular hyperplasia 728,
743
Fontan circulation 696
Forbes disease *see* glycogen
storage disease, type III
FOXA transcription factors 3, 5
fractures
in Alagille syndrome 222
in chronic liver disease 126
Francisella tularensis 678
free fatty acids, transport 587
fructose 635–7
fructose intolerance
see hereditary fructose
intolerance
fructose metabolism
biochemistry 442*f*, 442–3
inborn errors 442–7
(*see also* hereditary
fructose intolerance
(HFI))
fructose-1,6-diphosphatase 10,
443
deficiency 442, 447
FUCA1 mutations (α -L-
fucosidase) 556
fucosidosis 556–7
fulminant liver failure 268
fumarylacetoacetate 526
fumarylacetoacetate hydrolase
(FAH)
deficiency 527, 730
tyrosinemia 526, 528, 542
functional development of liver
10–21
bile formation 19–21
biotransformation 14–17
developmental changes
14–15*t*
circulating hormones 10
energy metabolism 10–14
amino acids 12–13
carbohydrates 11–12
lipids 13–14
enzymes 10–11
excretory function ontogeny
17*t*
hepatobiliary function 17–19
metabolic changes 11*t*
fungal infections of liver 688–91
aspergillosis 691
candidal infection 688–9
coccidioidomycosis 689, 690*f*
cryptococcosis 689–90
histoplasmosis 690–1, 691*f*
liver transplantation
complication 776
Penicillium marneffei infection
689
Trichosporon hepatitis 689
see also bile acid(s)
fungal toxins 35, 42
membrane adsorbent
recirculating system 47
furosemide 61
FXR *see* farnesoid X receptor
galactitol accumulation in
transferase deficiency
galactosemia
brain abnormalities 438
eye abnormalities 438
galactokinase 11
galactokinase deficiency
galactosemia 435, 441
cataracts 441
genetics 441
galactose metabolism
biochemistry 435–6, 436*f*, 438*f*
inborn errors 435–42
galactosemia
acute liver failure in children
36
epimerase deficiency 435,
441–2
galactokinase deficiency 435,
441
milk-induced 435
treatment 435
see also transferase deficiency
galactosemia
galactosialidosis 558
 β -galactosidase 553
gallbladder
congenital anomalies 247*t*,
247–8
congenital absence 247
diverticuli 248
double 248
malposition 248
multiple chambers 248
embryonic development 247*f*,
247
floating 248
heterotopic tissue in wall 248,
251*f*
hypoplasia 247–8
intraluminal pressure 19
motility impairment 252, 257
neonatal volume/contractility
19
porcelain 252

Index

- gallbladder (cont.)
 - stasis 257
 - torsion 248
 - transient distension of neonate 249
- gallbladder adenocarcinoma 173
- gallbladder adenoma 252
- gallbladder adenomyomatosis 252
- gallbladder adenomyosis 252
- gallbladder carcinoma 262
- gallbladder disease
 - acalculous 248–52
 - cholecystitis 250–1
 - dyskinesia 251–2
 - hydrops 248–9
 - inflammatory lesions 252
 - calculous 252–62
 - causes 253–4
 - classification 253
 - cholesterolosis 252
 - embryonal
 - rhabdomyosarcoma 252
 - malignant 252, 262
 - milk of calcium bile 252
 - tumors 252
 - wall thickening 248, 251*f*
see also gallstones
- gallbladder hydrops 249
- gallbladder Kasai procedure 167
- gallbladder polyps 252*f*, 252
- gallstones 252–62
 - biliary colic 259–60
 - causes 253–4
 - cholesterol 254*f*, 256–9, 261*f*, 261–2
 - classification 253
 - clinical features 259–60
 - genetic predisposition 259
 - imaging 260, 260*f*, 261*f*
 - incidence 253*f*
 - intestinal failure-associated
 - liver disease 235, 238
 - low phospholipid-associated syndrome 208
 - mucin promotion of formation 257
 - pain 259–60
 - pigment 254–6
 - black 255–6, 262
 - brown 255–6
 - Pima Indians 258*f*, 258
 - prevalence 252–3, 253*f*
 - silent 262
 - treatment 261–2
 - Wilson disease 473
 - see also* cholelithiasis
- gamma-glutamyltransferase 88, 91*t*, 91–2
- gastrointestinal bleeding 46
- gastroschisis 238–9
- gastrulation 1–2
- GATA transcription factors 3
- GATA1 mutations 521
- GATA6 transcription factor 3
- Gaucher cells 549–50
- Gaucher disease 546–52
 - biopsy 549
 - clinical variants 549
 - diagnosis 551
 - neuronopathic 549
 - pathology 549–51, 550*f*
 - prevalence 546–9
 - treatment 551–2
- GB virus 147
- GBA1 mutations (β -glucosidase) 546
- gene therapy
 - α_1 -antitrypsin deficiency 416
 - Crigler–Najjar syndrome 195
 - cystic fibrosis 432
 - mitochondrial hepatopathies 626
- genome-wide association studies 98
- germ layers 1–2
- gestational autoimmune liver disease 502–3
 - diagnosis 505*f*, 505–6
 - fetal iron store regulation 503
 - histopathology 503, 504*f*
 - preventive therapy 506
- Gilbert syndrome 190–3, 191*t*
 - age of onset 191
 - bile pigment composition 194*f*
 - diagnosis 193
 - genetic markers 191, 343
 - genetic testing 193
 - pathophysiology 191–3
 - UGT1A mutations 16, 180, 192–3
 - unconjugated
 - hyperbilirubinemia 95
- GLB1 mutations (β -galactosidase) 553–4
- globulins, serum levels 97
- globus pallidus 136
- glucagon
 - fetal circulation 10
 - surge at birth 12
- glucocorticoids
 - cholestasis treatment 116
 - fibrosis treatment 118
- glucokinase 11
- gluconeogenesis
 - fatty acid oxidation 14
 - fetal and neonatal 11–12
- glucose
 - glycogen storage disease type IA 450
 - neonatal release 12
 - oxidation 587
 - uptake by fetal liver 11
- glucose metabolism, fetal and neonatal 11–12
- glucose-6-phosphatase 447–8, 450*f*
 - gene mutations 449
 - glycogen storage disease type IA
 - deficiency 448–54, 451*f*, 453*f*
 - diagnostic assay 453
 - management 453*f*
 - glycogen storage disease type IB 455
- glucose 6-phosphate 447–8
 - deficiency 11
 - gluconeogenesis 12
- glucose-6-phosphate dehydrogenase deficiency 186, 192*f*
 - black pigment gallstones 255
- glucosidase, glycogen storage disease type IV treatment 458
- glucuronic acid, bilirubin conjugation 180
- β -glucuronidase 182
- glucuronosyltransferases 572
- glutamate 10, 12–13
- glutamine 13, 451
- glutamine synthetase 13
- gamma-glutamyl transpeptidase
 - benign recurrent intrahepatic cholestasis 201
 - in PFIC1 201
 - in PFIC3 208
- glutaric aciduria type III 595–6
- glutathione
 - acetaminophen hepatotoxicity 348
 - cocaine-induced
 - hepatotoxicity protection 352
 - sulfonamide hepatotoxicity 360
- glutathione S-transferases 16, 343
- carrier protein for bilirubin 180
- deficiency in Rotor syndrome 195
- glycine 12
- glycogen
 - degradation pathway 448*f*
 - hepatic in glycogen storage disease
 - type III 456
 - type IV 457
 - hydrolysis 447–8
 - metabolism 447–8
 - molecule structure 447
 - synthesis 11, 447, 448*f*
- glycogen debranching enzyme 455–6
- glycogen storage disease 447–58, 448*t*
 - hepatic adenoma association 730
 - subtypes 448–9
 - type IA 448–54
 - biochemical characteristics 450–2, 451*f*, 453*f*
 - clinical presentation 449–50
 - cornstarch feeding 454
 - diagnosis 453
 - hepatic adenoma 449–50, 452–3
 - hepatocellular carcinoma 449–50, 452–3
 - high-glucose diet 454
 - hyperlipidemia 450–1
 - hyperuricemia 451–2
 - hypoglycemia 450, 452
 - hypophosphatemia 452
 - lactic acidosis 450, 452
 - management 453*f*
 - molecular basis 449
 - phosphate 452
 - platelet dysfunction 452
 - portocaval shunting 454
 - prognosis 454
 - recurrent fever 452
 - TPN 453
 - treatment 453–4
 - type IB 454–5
 - glucose-6-phosphatase 455
 - molecular basis 455
 - neutrophil function 455
 - treatment 455
 - type II 559–60
 - adult onset 560
 - childhood/juvenile onset 560
 - diagnosis 560
 - infantile 559–60
 - pathology 559*f*, 560
 - phenotypes 559–60
 - treatment 560
 - type III 455–6
 - biochemical findings 456
 - clinical presentation 456
 - laboratory findings 456
 - molecular basis 455–6
 - treatment 456
 - type IV 457–8
 - biochemical features 457–8
 - clinical presentation 457
 - hepatocyte inclusions 457–8
 - laboratory findings 457
 - liver transplantation 458
 - molecular basis 457
 - pathologic features 457–8, 458*f*
 - treatment 458
 - glycoprotein degradation disorders 556–8
 - glycosaminoglycans 561–2
 - glycosylation in congenital disorders 706–7, 707*t*
 - glypigan 3 734
 - G_{M1}-gangliosidosis 553–4
 - GNPTAB mutations (phosphotransferase α - and β -subunits) 564

Index

- GNPTAG mutations
(phosphotransferase
γ-subunit) 564
- gold therapy 702
- GRACILE syndrome 611
- graft–recipient weight ratio for
liver transplantation
766–7
- graft-versus-host disease 701–2
ursodeoxycholic acid therapy
115
- Griscelli syndrome 379
- growth factors 53
liver regeneration 54
- growth failure
in Alagille syndrome 222, 225,
228
catch-up growth 784
in chronic liver disease 136–7
in end-stage liver disease 126
liver transplantation 784–5
in PFIC1 200
treatment 784–5
- growth hormone
cholestasis 124
growth failure after liver
transplantation 784–5
- Günther disease *see* congenital
erythropoietic porphyria
- gut lymphocyte homing
hypothesis 333
- HAV *see* hepatitis A virus
- HBV *see* hepatitis B virus
- haematopoiesis, fetal liver 10
- haloperidol 354
- halothane 35–6
drug-induced liver disease 354
hepatotoxicity mechanism 354
metabolism 354*f*, 354
- harderoporphyria 520
- hawkinsinuria 529
- HCV *see* hepatitis C virus
- HDV *see* hepatitis D virus
- health-related quality of life
after liver transplantation
785
- heart failure, causes 696
- heart transplantation 256
- HELLP syndrome 600
- hemangioendotheliomas 740
- heme biosynthesis
deficiencies 509
enzymes 509–11, 511*t*
pathway 510*f*
regulation 511–12
- heme conversion to bilirubin
177, 178*f*
- hemin 517
- hemochromatosis *see* neonatal
hemochromatosis (NH)
- hemoglobin
catabolism 177
synthesis 509–10
- hemoglobinopathies 698
in neonatal jaundice 186
- hemojuvelin 494, 500
- hemolysis in Wilson disease 474
- hemolytic disease, black pigment
gallstones 255, 262
- hemophagocytic
lymphohistiocytosis
acalculous cholecystitis 250
acquired 703
acute liver failure in children
36, 40
clinical features 378
diagnostic criteria 378, 379*t*
gene mutations 379, 380*t*
and immunodeficiency 378–80
liver transplantation 380, 763
pathology 379
treatment 380
- hemophagocytosis 378*f*
- hemophilia 698
- hemosiderosis, transfusion-
related 698
- Henoch–Schönlein purpura 249
- hepatic adenoma
see also hepatocellular
adenoma
glycogen storage disease
association 449–50,
452–3, 730
- hepatic arterial buffer response
694–5
- hepatic arterial thrombosis
778–9
- hepatic artery development 2
abnormalities in biliary atresia
160–1
- hepatic artery resistance index
167
- hepatic blood flow 695
- hepatic cells 1
- hepatic encephalopathy
see also minimal hepatic
encephalopathy
acute liver failure in children
32, 44–5, 763
stages 45*t*
ammonia
levels 97
role 64
antibiotic therapy 65
astrocyte pathology 64
bilirubin 188
branched chain amino acid
supplementation 65
calcineurin inhibitor toxicity
784
cirrhosis 56, 64–5
diagnosis 64
false neurotransmitter
hypothesis 64
- hepatic 54, 64–5
initiation 65
lactulose therapy 65
portal hypertension 69
protein restriction 65
stages 45*t*, 56*t*
treatment 65
- hepatic excretory function tests
88
- hepatic hypoperfusion 188
- hepatic osteodystrophy
in cholestasis 126
cirrhosis complication 57
- hepatic outflow obstruction
acute liver failure 42
liver transplantation
complications 780
- hepatic portocholecystectomy
167
- hepatic steatosis *see* steatosis
- hepatic stellate cells *see* stellate
cells
- hepatic stem cell tumors 750*f*
- hepatic transport efficiency 18
- hepatic vein thrombosis
Budd–Chiari syndrome
696–7
estrogen-induced 353
- hepatic veno-occlusive disease
115
- hepatic venous outflow
obstruction 696–8
- hepatic venous pressure gradient
measurement
in cirrhosis 54
in portal hypertension 77, 79
- hepatitis *see also* autoimmune
hepatitis; neonatal
hepatitis
Alagille syndrome 217
enterically transmitted non-A,
non-B 147
enteroviral 147–8
HDV 146–7
herpes 144
liver transplantation
complication 781
methotrexate-induced 357
neonatal giant cell 104
non-viral infectious 38
post-transfusion 147
syncytial giant cell 38
Trichosporon 689
tuberculous 142–3
typhoid 677–8
Wilson disease 472–3, 478–9,
481
- hepatitis A virus (HAV) 265–70
acute liver failure in children
37
acute phase 268
atypical 268
clinical features 267
diagnosis 267
epidemiology 266*f*, 266–7
food-borne outbreaks 266–7
genetics 268
genotypes 265
hosts 265
immunizations 265–6, 268–70
recommendations for use of
vaccine 269*t*, 270
incidence in USA 265, 267, 270
infection course 267*f*
infectivity 265–6
neonatal hepatitis 145
pathogenesis 267
prevalence 266–7
prevention 268–70
active immunization 269
efficacy of immunization
269
immunizations 265–6,
268–70, 269*t*
long-term immunogenicity
of immunization 269–70
passive immunization 268–9
public health implications 270
relapsing 268
transmission 266–7
treatment 268
vaccination 265–6
virus characteristics 265*f*,
265–6
- hepatitis B immunoglobulin
(HBIG) 289
- hepatitis B surface antigen
(HBsAg) 145–6
association with HDV 146–7
carrier mothers 276, 280, 284
HBV DNA detection 280–1
infectious virions 277
marker of new infections 277
maternal screening 289
spontaneous clearance in
chronic infection 283
- hepatitis B virus (HBV) 276–91,
277*t*
acute infection 281
acute liver failure in children
37
antiviral therapy indications
285–6
breastfeeding 280–1
chronic infection 281–3
DNA level changes 283
HBeAg seropositive phase
282
HBsAg spontaneous
clearance 283
histopathology 283–4
immune clearance phase
282
inflammatory phase 282
post-HBeAg seroconversion
phase 282
reactivation phase 282–3
clinical course 284*t*, 279*f*
core mutation 285
diagnosis 146, 279*t*
DNA levels 277–9, 278*t*, 285
changes in chronic infection
283
maternal load 280
epidemiology 279–80

Index

- hepatitis B virus (HBV) (cont.)
 - factors affecting natural course of infection 284–5
- fulminant hepatitis 281
 - prevention with vaccination 290
- genome 276*f*
- genotype 285
- geographic variability 279–80
- hepatocellular carcinoma
 - association 279, 282
 - core gene mutations 285
 - risk reduction with vaccination 290
- histopathology 283*f*, 283–4, 284*f*
- HIV coinfection 148, 377
- immune response suppression 285
- immune tolerance 280, 282, 284–5
- immunizations 289–91
 - HDV incidence reduction 291–2
- in immunodeficiency 376
 - primary 377–8
- incubation period 281
- latent infection 285
- liver failure 281
- malignancy association 279
- mutant development 285
- natural history of infection 281–4
- neonatal hepatitis 145–6
 - outcomes 280*t*
- precure mutations 281, 283, 285
- prevention 288–91
 - active immunization 289
 - booster doses of vaccine 290
 - effectiveness 289–90
 - HDV incidence reduction 291–2
 - long-term immunogenicity 290
 - passive immunization 289
 - universal vaccinations 289–90
 - vaccination program problems 290–1
- primary infections 277
- replication 277
- screening 145–6
- secretion by hepatocytes 277
- serologic markers 278*t*
- transmission
 - at delivery 280
 - horizontal 276, 280
 - intrauterine 280–1
 - perinatal (mother-to-infant) 276, 279–80
 - routes 280–1
- treatment 146, 285–8, 286*f*, 286*t*
 - antiviral therapy 285–8
 - combination therapy 288
 - currently approved therapy 286–8
 - virus characteristics 276–9
- hepatitis B virus immunoglobulin (HBIG) 383
- hepatitis Be antigen (HBeAg) 145, 280
 - carrier mothers 276, 284
 - HBV DNA detection 280–1
 - chronic infection marker 281–2
 - maternal screening 289
 - seroconversion 281–3
 - chronic infection after 282
 - rate 282
 - seropositive phase of chronic infection 282
- hepatitis C virus (HCV) 295–308
 - acute liver failure in children 37
 - AST:ALT ratio 90
 - chronicity 146
 - clinical features 300*f*, 300–1
 - counseling 306*t*
 - diagnosis 146, 299–300, 300*f*
 - early virologic response 306
 - epidemiology 297*f*, 297–8
 - extrahepatic manifestations 301
 - genome 295, 296*f*
 - genotypes 295–6
 - hepatocellular carcinoma association 301
 - histopathology 301–2, 302*f*
 - HIV coinfection 146, 148, 299, 377
 - IL28B* nucleotide polymorphisms 306–7
 - in immunodeficiency 376
 - primary 378
 - immunopathogenesis 296
 - neonatal hepatitis 146
 - prevention 308
 - risk factors 297–8
 - sustained virological response 302, 306, 307*f*
 - testing 298*t*, 300*t*
 - transmission 297–8
 - perinatal 298–9, 308
 - treatment 146, 302–5
 - adverse effects 304–5
 - autoantibody formation 304
 - contraindications 303*t*
 - direct acting antivirals 307–8
 - indications 303*t*
 - new therapies 307–8
 - prognostic factors for response to therapy 305–7
 - response-guided therapy 307
 - vaccine development 308
 - vertical transmission 146
 - viral persistence 296–7
 - virological responses 303*f*
 - virus characteristics 295–7, 296*f*
 - hepatitis D virus (HDV) 146–7, 277*t*, 291–2
 - clinical presentation 146–7, 291
 - epidemiology 291
 - pathogenesis 291
 - prevention 291–2
 - transmission 291
 - treatment 292
 - virology 291*f*, 291
 - hepatitis E antigen (HEVAg) 271
 - hepatitis E virus (HEV) 270–2
 - acute liver failure in children 37–8
 - antigen 271
 - anti-HEV seroprevalence 271
 - assays 271
 - clinical features 271–2, 272*t*
 - diagnosis 272
 - epidemiology 271
 - genotypes 271
 - histopathology 271–2
 - immune-mediated response 272
 - infection course 272*f*
 - management 272
 - neonatal hepatitis 147
 - pathogenesis 271–2
 - prevention 272
 - virus characteristics 270–1
 - hepatitis G virus 147
 - hepatobiliary disease
 - alkaline phosphatase serum levels 90–1
 - conjugated hyperbilirubinemia 95
 - 5′-nucleotidase serum levels 92
 - hepatobiliary scintigraphy in neonatal cholestasis 107–8
 - hepatoblastoma
 - acquired genetic abnormalities 744–51
 - classification 739*t*
 - diagnosis 733–4
 - differential diagnosis 743*f*
 - epidemiology 728–9
 - etiology 729–30
 - expression profiling 751
 - FAS* expression 751
 - fetal 741*f*, 742*f*
 - insulin-like growth factor axis activation 750–1
 - incidence 728
 - metastases 737
 - microRNA profiling 751
 - mixed 741*f*
 - molecular pathology 744–51
 - NOTCH pathway 750
 - pathogenesis 750*f*
 - pathology 737*f*, 737–9, 738*f*
 - prognosis 752*t*, 752–3
 - RNA profiling 751
 - small cell undifferentiated 740
 - sonic hedgehog pathway 749–50
 - staging 736*t*
 - treatment
 - arterial chemoembolization 755
 - chemotherapy 754, 764
 - liver transplantation 755, 764
 - radiation therapy 755
 - tyrosinemia 531, 537, 541
 - WNT signaling pathway 747–9
 - hepatoblasts 3
 - adhesion 3–5
 - β-catenin activity 3
 - differentiation 5*f*, 5–7
 - periportal 5–6
 - hepatocellular adenoma 742–3
 - estrogen-induced 353
 - incidence 728
 - hepatocellular carcinoma
 - acquired genetic abnormalities 751
 - Alagille syndrome association 218, 730
 - autoimmune hepatitis association 319
 - clinical presentation 733
 - diagnosis 733–4
 - differential diagnosis 743*f*
 - etiology 729–30
 - Gaucher disease 549
 - glycogen storage disease type IA 449–50, 452–3
 - HBV association 279, 282
 - core gene mutations 285
 - risk reduction with vaccination 290
 - HCV association 301
 - incidence 728
 - intestinal failure-associated liver disease 235
 - metastases 737
 - molecular pathology 751
 - NOTCH pathway 750
 - pathogenesis 750*f*
 - pathology 739
 - predisposition in cirrhosis 54
 - PFIC2 204
 - treatment
 - chemotherapy 754
 - interferon-alfa 755–6
 - liver transplantation 755, 764*t*, 764
 - radiation therapy 755
 - surgical 754
 - transcatheter arterial chemoembolization 755
 - tyrosinemia 530–1, 535, 541
 - nitisinone treated 539

Index

- hepatocellular cirrhosis 51–2
- hepatocellular mitochondria 343
- hepatocyte(s) 1–2
 - adaptation to cholestasis 28–9
 - bile acid
 - flux 25*f*, 26
 - retention 26–9, 29*f*
 - transport across plasma membrane 20
 - bile flow 26
 - bilirubin uptake 178–80
 - copper metabolism 466*f*
 - differentiation control by transcription factors 4*t*, 6
 - giant cell transformation 102, 104
 - in PFIC 104
 - globule-containing 413–14
 - HBV secretion 277
 - hepatoblast differentiation into 5
 - hepatotoxicity effects 344
 - Indian childhood cirrhosis 488
 - necrosis 42–4
 - neonatal hemochromatosis 503
 - non-alcoholic fatty liver disease 643
 - periportal 6
 - regeneration after injury 7, 42
 - swelling in inborn errors of metabolism 43–4
 - transplantation 48, 211
- hepatocyte growth factor 3
- hepatocyte nuclear factor (HNF)
 - HNF1 α 5, 406
 - HNF1 β 3, 7
 - haploinsufficiency 7
 - transcription factor 6
 - HNF4 406
 - HNF6 6–7
 - HNF β 406
- hepatoerythropoietic porphyria 518–19
- hepatolenticular degeneration *see* Wilson disease
- hepatomegaly
 - Alagille syndrome 217
 - cystic fibrosis 425–6, 428
 - glycogen storage disease type III 456
- hepatopuertoenterostomy *see* Kasai procedure
- hepatopulmonary syndrome
 - animal models 73
 - bile duct ligation model 73
 - cirrhosis 54–5
 - clinical features 55
 - echocardiography 74
 - liver transplant 74
 - management 55
 - portal hypertension 69, 73–4
 - pulmonary arteriovenous shunting 74
 - screening 74
- hepatorenal syndrome
 - acute liver failure 46
 - biliary atresia complication 168
 - in cirrhosis 62*t*, 62–3
 - clinical presentation 63
 - histology 63
 - inflammatory response 63
 - management 63
 - pathology 62–3
 - portal hypertension 69, 74
 - prognosis 63
 - renal replacement therapy 63
 - spontaneous bacterial peritonitis 63
 - urinalysis 63*t*
 - vasoconstrictor therapy 63
- hepatosplenomegaly 699
- hepatotoxicity/hepatotoxins 344–62 *see also* drug-induced liver disease
 - acute liver failure in children 34–6
 - classification 344–6, 346*t*
 - contingent 346
 - eliciting immunoallergic response 346
 - intrinsic 345–6
 - mechanism 343*f*, 346*f*
 - predictability 345
 - hepcidin 493–4
 - fetal iron store regulation 503
 - iron absorption role 495*f*
 - herbal medications 354–5
 - hereditary cholestasis with lymphedema 211–12
 - hereditary coproporphyria 519–20
 - hereditary fructose intolerance 442–7
 - biochemical features 444*t*, 444–5
 - clinical presentation 443–4, 449*t*
 - diagnosis 446
 - fructose-restricted diet 444
 - glycogenolysis inhibition 445
 - hepatic enzyme elevation 446
 - hyperuricemia 446
 - hypoglycemia 446
 - hypophosphatemia 446
 - laboratory findings 445–6
 - molecular basis 443
 - pathogenesis 444–5
 - pathology 43*f*
 - prognosis 447
 - renal tubular acidosis 446
 - treatment 446–7
 - urate excretion 446
 - hereditary hemochromatosis 493–8
 - approach to child with affected parent 498*f*, 498, 499*f*
 - clinical features 496–7
 - diagnosis 497–8
 - epidemiology 496
 - genetics 495–6, 496*f*
 - HFE mutations 495–6
 - iron absorption 495, 497*f*
 - organ involvement 497*t*
 - pathology 497*f*
 - screening 497–500, 499*f*
 - stages 496
 - treatment 500*t*, 500
 - hereditary oxoprolinemia 343
 - hereditary spherocytosis 186
 - hereditary tyrosinemia type 1 730
 - herpes simplex virus
 - acute liver failure in children 38
 - histology 144
 - neonatal hepatitis 144*f*, 144
 - treatment 144
 - heteroplasmy 604, 612
 - HEV *see* hepatitis E virus
 - hexokinase I 11
 - HFE
 - functions 496
 - genetic screening 498
 - iron absorption role 495*f*
 - mutations 495–6
 - β_2 -microglobulin heterodimer formation 495–6
 - Hhex transcription factor 3, 6–7
 - HHH syndrome 667
 - highly active antiretroviral therapy 376–7
 - histone deacetylase inhibitors 415
 - histoplasmosis (*Histoplasma capsulatum*) 690–1, 691*f*
 - HIV infection 376–7
 - HBV coinfection 148, 377
 - HCV coinfection 146, 148, 299, 377
 - hepatobiliary conditions 380*t*
 - incidence 376
 - liver disease 376
 - management 376–7
 - mortality 376
 - Mycobacterium avium* complex infection 679–80
 - neonatal hepatitis 148–9
 - opportunistic infections 149, 376–7
 - acalculous cholecystitis 250
 - pathology 376
 - HJV 500
 - HNF *see* hepatocyte nuclear factor
 - Hodgkin lymphoma 699
 - homoplasmy 604, 611
 - human copper transporter 466
 - human herpes virus 6
 - acute liver failure in children 38
 - neonatal hepatitis 148
 - human leukocyte antigens (HLA) 424
 - human papilloma virus 157
 - hydatid disease 674
 - hydrops of gallbladder 248–9
 - p*-hydroxyphenylpyruvate oxidase 12
 - 3-hydroxyacyl-CoA dehydrogenase deficiency 595
 - 25-hydroxylation pathway, side-chain oxidation defect 581
 - hydroxymethylbilane-synthase 510
 - gene mutations 516–17
 - 3 β -hydroxysteroid dehydrogenase/isomerase deficiency 115
 - 3 β -hydroxy- Δ^5 -C₂₇-steroid oxidoreductase deficiency 576–8
 - clinical features 576
 - diagnosis 576–7
 - pathogenesis 577*f*, 577
 - treatment 577–8
 - hyperammonemia 668
 - creatine deficiency 671
 - rapid response 670
 - hyperbilirubinemia
 - Alagille syndrome 217
 - American Academy of Pediatrics guidelines 184
 - antioxidant capacity of bilirubin 177
 - causes 184*t*
 - cirrhosis 58
 - conjugated 95, 102*t*, 150
 - disorders of 192*t*
 - neonatal cholestasis 150
 - syphilis 680
 - inherited forms 16
 - secondary 681
 - sepsis-associated 673
 - tertiary 681
 - unconjugated 95
 - disorders of 191*t*
 - neonatal cholestasis 104
 - hypercholanemia, physiologic of infancy 18
 - hypercholesterolemia 122
 - hyperhomocysteinemia 697
 - hyper-IgM syndrome 316, 374–5
 - CD40 ligand deficiency 374
 - clinical features 374
 - Cryptosporidium* oocysts 373*f*
 - Cryptosporidium parvum* prophylaxis 375
 - liver transplantation 374–5
 - malignancy association 374
 - X-linked 371
 - hyperlipidemia
 - in cholestasis 122–3
 - glycogen storage disease type 1A 450–1
 - treatment 122–3

Index

- hyperornithinemia–
 - hyperammonemia–
 - homocitrullinemia (HHH) syndrome 667
 - hyperpepcolic acidemia 658
 - hyperthyroidism 704
 - hypertriglyceridemia 94
 - hypertyrosinemia 528–30
 - inborn errors of metabolism 529
 - mental retardation 539
 - hyperuricemia
 - aldolase B deficiency 445*f*
 - glycogen storage disease type 1A 451–2
 - hereditary fructose intolerance 446
 - hypoglycemia
 - acute liver failure complication 46
 - glycogen storage disease
 - type IA 450, 452
 - type III 456
 - hereditary fructose intolerance 446
 - hypokalemia 46
 - hypophosphatemia
 - aldolase B deficiency 445*f*
 - glycogen storage disease type 1A 452
 - hereditary fructose intolerance 446
 - hypopituitarism 704
 - hypothyroidism 704–5
 - hypoxic liver injury 696
 - icterus 182
 - see also* jaundice
 - idiopathic copper toxicosis 465, 487, 490–1
 - clinical features 490
 - diagnosis 490
 - etiopathogenesis 490–1
 - histopathology 490
 - treatment 491
 - IL28B nucleotide polymorphisms 306–7
 - ileal bypass, partial 123
 - ileal exclusion
 - hyperlipidemia treatment 123
 - pruritus treatment 121–2
 - ileal resection 258
 - ileocecal valve absence 239
 - imiglucerase 551
 - iminosugar compounds 415
 - immune defenses, liver role 370–1
 - immune dysregulation
 - acute liver failure in children 36, 42
 - cirrhosis 57
 - immune response
 - adaptive 370
 - innate 370
 - pharmacological manipulation 381–3
 - immune tolerance in liver
 - transplantation 775–6
 - immunizations
 - cholestasis 137
 - HAV 265–6, 268–70
 - active 269
 - adverse effects 270
 - efficacy 269
 - long-term immunogenicity 269–70
 - passive 268–9
 - recommendations for use of vaccine 270
 - recommended ages/dosages 269*t*
 - HBV 145, 147, 289–91
 - booster doses 290
 - effectiveness 289–90
 - HDV incidence reduction 291–2
 - long-term immunogenicity 290
 - universal vaccinations 289–90
 - vaccination program
 - problems 290–1
 - WHO recommendations 291
 - rubella virus 145
- immunodeficiency 370–83
 - adenosine deaminase deficiency 375
 - chronic granulomatous disease 381
 - combined 373*f*
 - common variable 375
 - cryptosporidiosis management 375
 - hepatic complications 371–3
 - malignancy association 374
 - multiple intestinal atresia 375
 - opportunistic infections 371
 - pharmacological manipulation of immune response 381–3
 - primary 371, 372*t*
 - HBV 377–8
 - HCV 378
 - inheritance 371
 - liver transplantation 375
 - management 371
 - with sclerosing cholangitis 377*t*
 - recurrent infections 371
 - secondary 371
 - viral hepatitis 376
 - X-linked proliferative disease 380–1
 - see also* hemophagocytic lymphohistiocytosis; HIV infection; hyper-IgM syndrome; sclerosing cholangitis
- immunoglobulins 97
- immunologic tolerance 370–1
- immunology of liver 41
- immunosuppression in liver
 - transplantation 169, 774*t*, 774–6, 775*f*
 - dose reduction 775–6
 - graft rejection 775
 - long-term maintenance 775–6
- immunosuppressive agents,
 - hemophagocytic lymphohistiocytosis treatment 380
- inborn errors of metabolism
 - amino acid disorders 387*t*
 - laboratory testing 396–7
 - newborn screening 397–8
 - fatty acid oxidation disorders 387*t*
 - autopsy screening 397*f*
 - laboratory testing 393–6, 394*t*, 395*f*
 - newborn screening 397–8
 - hypertyrosinemia 529
 - laboratory diagnosis 387–98
 - laboratory investigations 388–9
 - lactic acidemias 390–3, 392*t*
 - misdiagnoses 387*t*
 - mitochondrial hepatopathies 617–18
 - neonatal cholestasis 107
 - neonatal screening 397–8
 - organic acidurias 387*t*
 - laboratory testing 390, 391*t*
 - newborn screening 397–8
 - signs/symptoms recognition 388
 - urea cycle disorders 387*t*, 396
 - see also* carbohydrate metabolism, inborn errors; fatty acid oxidation disorders, inborn errors; tyrosinemia
- Indian childhood cirrhosis 465, 487–90
 - clinical features 487–8
 - copper chelation therapy 488–9
 - copper ingestion reduction 489–90
 - copper levels 489
 - diagnosis 489
 - epidemiology 487
 - genetics 487
 - histopathology 488, 488*f*
 - management 488–9
 - pathogenesis 488–9
 - prevention 489–90
- indocyanine green,
 - hepatocellular transport 18, 59
- infant formula milk
 - lactose-free 437, 440
- medium chain triglycerides 126
- infantile hemangioendothelioma 751
- infantile hemangiomas 740
- infantile obstructive cholangiopathy 148
- infantile Refsum disease 581–2, 653, 655
 - clinical findings 658
 - pathology 658
- infections
 - catheter-associated 241
 - liver transplantation
 - complications 773, 776–7
 - systemic disease 694–5
 - see also* bacterial infections; fungal infections; liver abscess; parasitic diseases of liver; rickettsial disease; viral infections
- inflammatory bowel disease, sclerosing cholangitis association 322, 324, 326–7, 330*f*
- colorectal cancer risk 337
- inflammatory injury 42
- inflammatory infiltrate in hepatocytes 44
- systemic infection 695
- infiximab 355
- insulin
 - fetal liver 11
 - neonatal 12
 - resistance and non-alcoholic fatty liver disease association 633
- insulin-like growth factor 1 124
- insulin-like growth factor axis
 - activation 750–1
- intellectual impairment
 - see* cognitive impairment
- intensive care unit, hepatic dysfunction in 694
- interferon-alfa
 - HBV treatment 286*t*, 287–8
 - HCV treatment 303
 - adverse effects 304–5
 - response to therapy 305–7
 - HDV treatment 292
 - hepatocellular carcinoma treatment 755–6
- interferon-alfa, pegylated
 - HBV treatment 287
 - HCV treatment 303–4
 - HDV treatment 292
 - HEV treatment 272
- international normalized ratio 88
- intestinal failure
 - causes 234*t*
 - definition 234
 - etiology 234
 - management 241
 - parenteral nutrition 234

Index

- intestinal failure-associated liver disease 234–43
 - see also* TPN-associated cholestasis
 - biliary sludge formation 235, 238
 - cholelithiasis 235, 238
 - cholestasis 234–6
 - clinical presentation 234–5
 - gastroschisis 238–9
 - histopathology 235–6, 236*f*, 237*t*
 - malignancy risk 235
 - natural history 234–5
 - pathogenesis 236–7, 237*f*
 - risk factors 236–7
 - contaminants 241
 - parenteral nutrition factors 239–41
 - patient factors 237–9
 - surgical etiology 238–9
 - survival 235*f*, 235
 - treatment 241–3
 - liver transplantation 243
 - parenteral nutrition modification 242*f*, 242–3, 243*f*
 - pharmacological management 243
 - intestinal stasis in intestinal failure-associated liver disease 238
 - intracranial bleeding, Alagille syndrome 220
 - intracranial pressure monitoring in hepatic encephalopathy 45
 - intrahepatic bile duct development 5–6
 - JAGGED/NOTCH signaling pathway 6
 - paucity 6–7
 - tubulogenesis 6
 - intrahepatic cholestasis of pregnancy 204
 - gene mutation 208
 - treatment 211
 - intravenous gammaglobulin 186, 382
 - neonatal hemochromatosis treatment 506, 762–3
 - iron
 - in cholestasis 136
 - metabolism 494*f*
 - regulatory mechanisms 493–4
 - iron-deficiency anemia 136
 - iron storage disorders 493–506
 - iron overload 493–5, 498–500
 - biopsy 499
 - classification 493*t*
 - diagnosis 498
 - genetic screening 498
 - secondary 500–2
 - see also* hereditary hemochromatosis; juvenile hemochromatosis; neonatal hemochromatosis
 - prognosis 167
 - sequential approach 169
 - survival rate 170
 - contraindication in Alagille syndrome 228
 - liver transplant following failure 168
 - prognosis 167
 - reoperation following 167–8
- kava 42
- Kawasaki syndrome 704
- hydrops of gallbladder 248–9
- Kayser–Fleischer ring 471*f*, 471–2
- Wilson disease diagnosis 477–8, 480, 482
- Kell antigens, neonatal jaundice 186
- kernicterus 188
 - Crigler–Najjar syndrome 193
- 3-ketoacyl CoA thiolases 591
- ketoconazole 356
- ketone bodies 14, 592
- ketosis, physiological 396*t*
- kidney
 - calcineurin inhibitor toxicity 784
 - cystic disorders 710–11
 - glycogen storage disease type IA 450
 - hereditary fructose intolerance 446
 - neonatal hemochromatosis pathology 503–4
 - renal disease in Alagille syndrome 225*f*, 225
 - transferase deficiency galactosemia 438–9
 - tyrosinemia 541–2
 - imaging 535
 - pathology 537
 - renal involvement evaluation 534*t*
 - Wilson disease clinical features 474
- kifunensine 415
- Kupffer cells 1–2, 41
 - innate immune response 370
- kwashiorkor 705
- labor induction, neonatal jaundice 186
- laboratory assessment 88–98
 - amino acid plasma and urine levels 97–8
 - cholestasis tests 88, 90–2
 - exogenous substances in quantitative liver function tests 96–7
 - genome-wide association studies 98
 - hepatic excretory function tests 88, 89*t*, 97
 - impaired bile flow tests 88, 90–2
 - liver disease 88–9
 - liver injury detection tests 88–90, 89*t*
 - liver synthetic capacity tests 88, 89*t*, 92–4
 - metabolic function tests 88, 89*t*, 94–6
 - screening 88
 - serum chemistry tests 88
 - serum globulins 97
 - see also specific tests and conditions*
- lactate, neonatal 11–12
- lactate dehydrogenase 88, 90
- lactate:pyruvate ratio 390
- lactic acidemias, laboratory testing 390–3, 392*t*
- lactic acidosis, glycogen storage disease type IA 450, 452
- lamivudine 287–8
- lamotrigine 356
- Langerhan cell histiocytosis 324*f*
- L-asparaginase 350
- leaky gut hypothesis of primary sclerosing cholangitis 333
- learning disabilities *see* cognitive impairment
- lecithin–cholesterol acyltransferase 94
- leishmaniasis (*Leishmania*) 688
- leptospirosis (*Leptospira interrogans*) 681–2
 - acalculous cholecystitis 250
 - acute liver failure in children 38
 - clinical manifestations 681
 - laboratory findings 681
 - pathophysiology 681, 682*f*
 - treatment 682
- leucine 12
- leucine aminopeptidase 92
- leukemia 699
 - acute liver failure in children 38
- leukocytes 1–2
- limit dextrinosis *see* glycogen storage disease, type III
- linoleic acid 127, 239–40, 592
 - in fatty acid oxidation disorders 599
- linolenic acid 127, 592
 - in fatty acid oxidation disorders 599
- LIPA mutations (lysosomal acid lipase) 560
- lipid(s) 94
 - bile composition 257–8
 - metabolism in fetal and neonate liver 13–14
 - in non-alcoholic fatty liver disease 634–5
- lipid emulsions modification 243*f*

Index

- lipid emulsions (cont.)
 - parenteral nutrition 239–41
 - composition 240*t*
 - modification 242–3, 243*f*
- lipid storage diseases 579–80
- lipopolysaccharide in sepsis-associated cholestasis 27–8
- lipoprotein(s) 94
- lipoprotein X (LPX) 122
- listeriosis (*Listeria monocytogenes*) 678–9
- lithocholic acid 572
- liver abscess
 - chronic granulomatous disease 381
 - Entamoeba histolytica* infection 683–4
 - pyogenic 673–5
 - tuberculosis 679
 - Yersinia enterocolitica* 678
- liver bud formation and expansion 2*f*, 2–5
 - β-catenin 3
 - hepatocyte growth factor 3
 - inductive signaling 3–5
 - TGFβ 3–5
 - transcription factors 3, 4*t*
 - WNT family of glycoproteins 3
 - WNT signaling 3
- liver cell adenoma
 - see* hepatocellular adenoma
- liver cell dysplasia in tyrosinemia 535–7, 536*f*
- liver cytosol-1 antibodies 311–12
- liver development 1–7
 - cardiogenic mesoderm 1*f*, 2–3
 - epithelial differentiation stage 2
 - hematopoietic cells 5
 - hepatoblasts 3
 - liver bud formation and expansion 2–5
 - microRNA 6
 - septum transversum mesenchyme 1*f*, 2–3
 - specification 1*f*, 2–3, 4*t*
 - stages 5
 - transcription factors 3, 4*t*
 - FOXA 3, 5
 - GATA 3
 - GATA6 3
 - Hhex 3, 6–7
 - HNF1α 5
 - HNF1β 3, 6–7
 - HNF6 6–7
 - OC2 6
 - Prox1 3
 - Sox17 7
 - Tbx3 3, 5
 - Yap1 5
 - Wnt family 2–3
 - see also* extrahepatic bile duct, development; functional development of liver; intrahepatic bile duct, development
- liver disease, laboratory assessment 88–9
- liver disease-specific induced pluripotent stem cells 543
- liver failure *see also* acute liver failure in children
 - HBV fulminant infection 281
 - immunologic disturbance 371
 - treatment in autoimmune hepatitis 318
- liver fluke 687*f*, 687–8
- liver function tests 88
 - exogenous substances in 96–7
- liver injury, laboratory assessment 88–90, 89*t*
- liver–kidney microsome type-1 antibodies 312
 - autoimmune hepatitis 311
 - autoimmune hepatitis-like hepatotoxicity 344–5
- liver progenitor cells 7
- liver transplantation 760–70
 - acute intermittent porphyria 517
 - acute liver failure 47–8, 763
 - decisions 33, 47–8
 - organ allocation 48
 - outcomes 48–9
 - Alagille syndrome 218, 228, 761
 - survival 226
 - allograft outflow 770
 - antibiotics 777
 - post-transplant prophylaxis 773
 - anticoagulation therapy 773–4
 - α₁-antitrypsin deficiency 401, 415
 - autoimmune hepatitis 319–20
 - auxiliary partial orthoptic transplantation 48, 769
 - bile duct reconstruction 770
 - biliary atresia 155–6, 168–70, 761
 - outcome 170
 - primary therapy for 169–70
 - biliary strictures 777
 - calcineurin inhibitors 774–5
 - dose reduction 775
 - side effects 784
 - Caroli disease/syndrome 719–20
 - cholestasis 111, 761
 - chronic comorbidities 784
 - cirrhosis 59
 - cognitive impairment 785
 - complications 778–81
 - biliary 780–1
 - biliary strictures 782*f*
 - hepatic arterial thrombosis 778–9
 - hepatic outflow obstruction 780
 - hepatitis 319–20, 781
 - portal vein thrombosis/stenosis 779–80
 - congenital hepatic fibrosis 716
 - contraindications 761
 - Crigler–Najjar syndrome 195
 - cystic fibrosis 431, 764
 - cytomegalovirus
 - febrile patient evaluation 777
 - risk 773, 776–7
 - treatment 777
 - developmental delay 785
 - donor liver procurement 769
 - donor organs options/selection 766–9, 768*t*
 - donor age 768
 - donor stability 767–8
 - graft–recipient weight ratio 766–7
 - living donor selection 768–9
 - drug-induced liver disease 362
 - Epstein–Barr virus
 - febrile patient evaluation 777
 - infection risk 170, 773, 777
 - erythropoietic protoporphyria 523
 - ethical issues 769
 - evaluation process 760*t*, 760–1
 - selection criteria 765*t*
 - febrile patient evaluation 777
 - Gaucher disease 551
 - glycogen storage disease type IV 458
 - graft dysfunction evaluation 777–8
 - graft function assessment 774
 - graft injury 778–9
 - graft rejection 49, 775*f*
 - acute 775, 776*f*
 - graft survival 782
 - growth failure 784–5
 - health-related quality of life 785
 - hemophagocytic lymphohistiocytosis 380, 763
 - hepatoblastoma 755, 764
 - hepatocellular carcinoma 755, 764*t*, 764
 - hepatocellular mass 766–7
 - hepatopulmonary syndrome 55, 74
 - hyper-IgM syndrome 374–5
 - hyperlipidemia treatment 123
 - idiopathic copper toxicosis 491
 - immune suppression 169, 774*t*, 774–6, 775*f*
 - dose reduction 775–6
 - graft rejection 775
 - long-term maintenance 775–6
- indications 761
- infectious complications 773, 776–7
 - bacterial 776–7
 - early 776–7
 - febrile patient evaluation 777
 - fungal 776
 - long-term follow-up 777
 - viral 773, 776–7
- intestinal failure-associated liver disease 243
- liver cell transplant 48
- living-donor transplantation 48, 766, 767*f*, 768–9
- living-related 228
- MELD/PELD scoring 764–5, 765*f*
- metabolic disease 761–3, 769
- mitochondrial hepatopathies 626, 763
- neonatal hemochromatosis 506
- non-alcoholic fatty liver disease 646
- operative techniques 767*f*, 769
- optimal arterial inflow 769
- outcomes
 - long-term 782–4
 - on waiting list 766*t*, 766
- PFIC 207–8, 761
- pharmacological manipulation of immune response 382
- portal hypertension 68, 81, 431
- post-transplant care 773–86
 - antibiotic prophylaxis 773
 - early management 773–4
 - viral infection risk 773
- primary immunodeficiency 375
- primary liver diseases 761, 762*t*
- prioritization 764–5
- reduced-size technique 169, 766, 767*f*
- retransplantation 764, 782–4
- sclerosing cholangitis 336
 - prognosis 337
- split-liver 766
 - donors 768*t*, 768
 - operative technique 767*f*, 769
- survival 782, 783*f*, 783*t*
- technical aspects 769–70
- tumors of liver 755, 763–4
- tyrosinemia 531*t*, 540–1, 762
 - renal involvement 542
- urea cycle disorders 670, 761
- whole organ 766

Index

- Wilson disease 481, 486
 xanthoma treatment 123
 liver–kidney microsomal
 antibody 36
 long-chain 3-hydroxyl-CoA
 dehydrogenase deficiency
 594, 617
 ethanol toxicity 620
 isolated 594
 long-chain acyl-CoA
 dehydrogenase 589–90
 lovastatin 123
 low density lipoprotein
 triglyceride 94
 low phospholipid-associated
 cholelithiasis syndrome
 208, 211
 Lucey–Driscoll syndrome 187
 lung transplantation 416
 lupus erythematosus, neonatal
 149, 703
 Lyme disease 681
 lymphedema, hereditary
 cholestasis with 211–12
 lymphomas 699
 lysinuric protein intolerance 668
 lysophosphatidic acid 119
 lysosomal acid lipase deficiency
 560–1
 lysosomal storage diseases
 546–65
 glycogen storage disease type
 II 559–60
 glycoprotein degradation
 disorders 556–8
 lysosomal acid lipase
 deficiency 560–1
 management 546
 mucopolidosis types II and III
 563–4
 mucopolysaccharidoses 561–3
 multiple sulfatase deficiency
 564–5
 pathology involving liver 546,
 548*t*
 screening 546
 sphingolipidoses 546–54
 see also Niemann–Pick disease
 type C
 lysosomes 546, 547*f*
 macrophage activation syndrome
 379, 703 *see also*
 hemophagocytic
 lymphohistiocytosis
 magnesium, in cholestasis 135
 magnetic resonance
 cholangiography 108
 magnetic resonance
 cholangiopan-
 creatography 429
 magnetic resonance imaging
 see MRI
 malabsorption
 Alagille syndrome 228
 in cholestasis 123–4
 short bowel syndrome 238
 malaria 688
 maleylacetoacetate 526
 malnutrition 705–6
 Alagille syndrome 225, 228
 in cholestasis 123–4
 chronic liver disease 65–6
 cirrhosis complication 57, 65–6
 malonyl-CoA 587–8
 manganese
 avoidance in parenteral
 nutrition 242
 in cholestasis 136
 intestinal failure-associated
 liver disease 241
 α-mannosidosis 557
 maple syrup urine disease 396–7
 matrix metalloproteinases 53
 liver regeneration 54
 Mauriac syndrome 705
 MDR3 disorders
 intrahepatic cholestasis of
 pregnancy 208
 low phospholipid-associated
 cholelithiasis syndrome
 208
 mutations of gene (*ABCB4*)
 208
 neonatal cholestasis 208
 PFIC3 208, 210
 mechanical ventilation, hepatic
 dysfunction 694
 meconium ileus, and cystic
 fibrosis 424
 medium-chain 3-ketoacyl CoA
 thiolase deficiency
 deficiency 595
 medium-chain acyl-CoA
 dehydrogenase 590
 medium-chain acyl-CoA
 dehydrogenase deficiency
 594–5
 carnitine supplementation 599
 clinical features 594–5
 cognitive impairment 595
 dietary fat restriction 599
 fasting in 598
 pathogenesis 594
 screening 595
 medium-chain ketoacyl-CoA
 thiolase 591
 medium-chain triglycerides in
 infant formula 126
 membrane adsorbent
 recirculating system in
 acute liver failure 47
 men who have sex with men,
 HAV association 267
 menadione *see* vitamin K
 menaquinone *see* vitamin K
 Menkes disease gene 470
 6-mercaptopurine
 autoimmune hepatitis
 treatment 317
 drug-induced liver disease 350,
 352
 mesenchymal hamartomas 742,
 749*f*
 genetics 751
 incidence 728
 mesoderm 1–2
 metabolic bone disease 222
 metabolic disease, hepatic-based
 acute liver failure 36–7, 37*t*,
 39–40
 hepatocyte lesions 43–4
 liver transplantation 761–3,
 769
 tumors of liver 732*f*
 metabolic syndrome, non-
 alcoholic fatty liver
 disease association 634,
 637–8
 metallochaperones, copper
 homeostasis role
 467
 metformin supplementation 645
 methionine 13
 dietary control in tyrosinemia
 540
 methotrexate
 drug-induced liver disease
 356–7, 702–3
 fibrosis association 356
 hepatitis association 357
 hepatotoxicity mechanism 357
 surveillance for liver damage
 356–7
 2-methylacyl Co-A racemase
 deficiency 580–1
 α-methylacyl-CoA racemase
 deficiency 653–4
 deficiency 656, 660
 3,4-methylenedioxymetham-
 phetamine (MDMA)
 352–3
 mevalonic aciduria (mevalonate
 kinase deficiency) 654,
 656, 659–60
 hepatic abnormalities 660
Microsporidium, HIV
 opportunistic infection
 376–7
 miglustat 551
 minimal hepatic encephalopathy
 64
 cirrhosis 56
 minocycline
 autoimmune hepatitis trigger
 314, 316
 drug-induced liver disease
 357
 sclerosing cholangitis
 treatment 335–6
 miR-30 6
 mitochondria
 functions 605*f*, 605–6
 genetics 604
 hepatocellular 343
 in non-alcoholic fatty liver
 disease 635
 oxidative phosphorylation
 605*f*
 structure 603–4
 mitochondrial DNA (mtDNA)
 603–4
 mutations 606–7
 mitochondrial DNA depletion
 syndrome 611–13
 clinical presentation 611–12
 diagnosis 612
 genetics 612–13
 hepatocerebral form 611–13
 histopathology 612, 612*f*, 613*f*
 myopathic form 611, 613
 mitochondrial
 encephalomyopathies
 607*t*
 neurogastrointestinal 616–17
 mitochondrial genes, mutations
 603
 mitochondrial hepatopathies
 603, 606–27 *see also* long-
 chain 3-hydroxyl-CoA
 dehydrogenase deficiency
 acute liver failure in children
 36–7, 40–2
 chronic diarrhea and intestinal
 pseudo-obstruction
 with liver involvement
 616
 classification 607–10
 genotypic 609–10
 phenotypic 607–9, 608*t*
 clinical features 603*t*, 627*t*
 diagnosis 621
 definitive tests 622–4
 prenatal 626–7
 drug toxicity 619–20
 electron transport deficiency
 617–18
 epidemiology 606*f*, 606–7
 fatty acid oxidation disorders
 617–18
 histopathological
 investigations 623
 hydrophilic bile acid toxicity
 620–1
 imaging 623
 later-onset progressive liver
 failure 613–14
 molecular analysis 623–4
 neonatal liver failure 610–11
 neuromuscular 607
 non-alcoholic fatty liver
 disease/steatohepatitis
 621
 pancreatic insufficiency, bone
 marrow abnormalities
 and liver involvement
 614–16
 primary 607–18
 molecular classification 609*t*
 screening tests 621–2, 622*t*

Index

- mitochondrial hepatopathies (cont.)
 - secondary 607–9, 618–21
 - treatment 624–6, 625*t*
 - antioxidants 624–6
 - cell-based therapy 626
 - dietary 626
 - gene therapy 626
 - liver transplantation 626, 763
- mitochondrial neurogastrointestinal encephalomyopathy 616–17
- mitochondrial respiration measurement 622–3
- Model for End-Stage Liver Disease (MELD) scoring system 764–5, 765*f*
- outcomes on waiting list 766
- molecular adsorbent recirculating system 122
- monoclonal antibodies in liver transplantation 382
- monoethylglycineylidide test 96
- moyamoya disease 221*f*, 221
- MRI (magnetic resonance imaging)
 - cystic fibrosis 429
 - Wilson disease diagnosis 480–1
- mucin glycoproteins 255
- mucin hypersecretion in cystic fibrosis 423
- mucopolidosis types II and III 563–4
- mucopolysaccharidoses 561–3, 563*t*
 - clinical features 562
 - diagnosis 562
 - pathology 562
 - treatment 562–3
- multidrug resistance protein 3, *see* MDR3
- multidrug resistance-related protein 2 (MRP2) 17, 20–1
 - impaired expression 25–6
- multifunctional enzyme 2 *see* D-bifunctional protein
- multiple acyl-CoA dehydrogenation deficiency 595–6
- multiple intestinal atresia 375
- multiple sulfatase deficiency 564–5
- MURR1 467–8
- Mycobacterium avium* complex 149, 679–80, 680*f*
- Mycobacterium tuberculosis*, opportunistic infection in HIV 149
- mycophenolate mofetil 318–20
- myeloproliferative disorder 697
- myocardial hypertrophy 537
- myocerebrohepatopathy *see* POLG1 (polymerase gamma) disease
- myofibroblasts 53
- N-acetylcysteine, acetaminophen hepatotoxicity treatment 34, 347–8, 362
- N-acetyl-*p*-benzoquinone imine 348
- N-acetyltransferase 2 16
- Na⁺/K⁺-ATPase 19
- nails/nail changes in cirrhosis 54
- naloxone 120
- naltrexone 120–1
- nasobiliary drainage, pruritus treatment 122
- natural killer cells 41
 - innate immune response 370
- natural killer T-cells 41
 - innate immune response 370
- Navajo neurohepatopathy 613, 617
- necrotizing enterocolitis 238
- Neisseria meningitidis* 38
- neonatal cholestasis *see* cholestasis, neonatal
- neonatal giant cell hepatitis 104
- neonatal hemochromatosis 502–6
 - acute liver failure in children 36, 40
 - diagnosis 504–6
 - differential diagnosis 505
 - etiology 502–3
 - extrahepatic siderosis 503–5
 - fetal iron store regulation 503
 - gestational autoimmune liver disease 502–3
 - diagnosis 505*f*, 505–6
 - fetal iron store regulation 503
 - histopathology 503, 504*f*
 - preventive therapy 506
 - histopathology 503
 - intravenous immunoglobulin prophylaxis 382
 - pathogenesis 502–3
 - pathology 503–4
 - phenotype 502
 - prophylaxis, intravenous immunoglobulin 382
 - renal failure 503–4
 - treatment 506
 - double volume exchange transfusion 506, 762–3
 - intravenous immunoglobulin 506, 762–3
 - liver transplantation 506
 - medical therapy 506
 - preventive 506
- neonatal hepatitis 102–4, 151
 - see also* specific types of hepatitis
 - biliary atresia differential diagnosis 150
 - biopsy 141*f*
 - cholestasis 140
 - differential diagnosis 150
 - clinical presentation 150
 - differential diagnosis 150
 - etiology of 140–50
 - bacterial infections 140–3
 - chromosomal disorders 149
 - Coombs-positive giant cell hepatitis 150
 - familial intrahepatic cholestatic syndromes 149
 - lupus erythematosus 149
 - protozoan infections 143
 - pseudo-TORCH syndrome 149–50
 - viral infections 143*f*, 143–9, 144*f*, 145*f*
 - familial form 150
 - giant cell transformation 150–1, 151*f*, 164*f*
 - histopathology 140, 141*f*, 150–1
 - idiopathic 155
 - imaging 150
 - infection routes 140
 - perinatal acquisition 140
 - postnatal infection 140
 - prognosis 151
 - sporadic form 150
 - transplacental infection 140
- neonatal ichthyosis–sclerosing cholangitis syndrome 325
- neonatal jaundice 182, 184–90
 - bilirubin
 - decreased excretion 186–8
 - levels 184, 188
 - bilirubin encephalopathy 188
 - brainstem auditory evoked potentials 188
 - breast-feeding association 187, 190
 - causes 184*t*
 - clinical evaluation 185*f*
 - drug-induced 187
 - epidemiologic risk factors 184
 - extravascular blood 186
 - fetal–maternal blood group incompatibility 185–6
 - hemoglobinopathies 186
 - hepatic hypoperfusion 188
 - hormone-induced 187
 - increased bilirubin production 185–6
 - infants of diabetic mothers 187
 - kernicterus 188
 - management 188–90
 - breast-feeding optimization 190
 - exchange transfusion 190
 - pharmacological 190
 - phototherapy 188–9
 - physiologic 184
 - polycythemia 186
 - prematurity 187
 - somatosensory evoked potentials 188
 - toxicity 188
- neonatal lupus 149, 703
- neonatal-onset adrenoleukodystrophy 581–2, 655, 658
- neonates
 - cholestasis differential diagnosis 102–4
 - CYP450 enzyme activity 343
 - gamma-glutamyltransferase levels 91
 - liver failure in mitochondrial hepatopathies 610–11
 - screening for inborn errors of metabolism 397–8
 - transient hyperammonemia 668
- neuraminidase 558
- neutrophils 695
- nevirapine 357
- nicotinic acid 193
- Niemann–Pick disease type A 552–3
- Niemann–Pick disease type B 552–3
- Niemann–Pick disease type C 554–6
 - acute liver failure in children 36
 - adolescent/adult onset (type 2) 555
 - biopsy 555
 - childhood-onset (type 1) 554–5
 - diagnosis 556
 - gene mutations 555
 - histopathology 555
 - phenotypes 554
 - treatment 556
- nimesulide 358
- nitisinone (NTBC), tyrosinemia treatment 533, 537–9, 762
 - compliance 543
 - complications 538–9
 - dietary control 539, 543
 - monitoring 543
 - protocols 537–8
 - results 538
- nitric oxide
 - hepatic microcirculation regulation 695–6
 - hepatopulmonary syndrome 73
 - in portal hypertension 72
- nitrofurantoin 35–6
- nitrogen 664–5

Index

- nodular regenerative hyperplasia
azathioprine-induced 352
portal hypertension 71
- non-absorbable ion exchange
resins
hyperlipidemia treatment 123
pruritus treatment 119–20
- non-alcoholic fatty liver disease
631–46
ALT, serum 632–3, 637–9
anthropometrics 638
apolipoprotein C3 (*APOC3*)
mutant 635
biopsy 640
burden 631
clinical features 637
diagnosis 637–40
endoplasmic reticulum stress
635
epidemiology 631–4, 632*t*
fibrosis 633
fructose 635–7
genetics 635
in hemophilia 698
hepatocyte ultrastructural
change 643
histopathology 640–3, 642*f*,
644*f*
imaging 639*f*, 639
insulin resistance association
633
laboratory tests 638–9
lipids 634–5
liver disease progression 633
metabolic syndrome
association 634, 637–8
mitochondria 635
mitochondrial hepatopathies
621
mortality 633–4
nature vs. nurture 2 hit
hypothesis 637
nutrigenomics 635–7
obesity association 631, 633,
637–8
pathogenesis 634–7, 636*f*
prevalence 631–2, 632*t*
research tests/panels 639
risk factors 637–8
screening 632–3, 637–9
total and central body
adiposity 10
treatment 643–6
antioxidants 645
bariatric surgery 646
dietary 643–5
liver transplantation 646
management algorithm 641*f*
weight control 643
- non-alcoholic steatohepatitis 631
activity scores 642–3
burden 631
endoplasmic reticulum stress
635
fructose 635–7
- hepatic steatosis differential
diagnosis 632*t*
hepatocyte ultrastructural
change 643
histopathology 640–1
lipids 634
mitochondria 635
mitochondrial hepatopathies
621
pathogenesis 636*f*
prevalence 631
treatment 643–6
types 643
- non-Hodgkin lymphoma 699
- non-ketotic hyperglycinemia
396–7
- non-nucleoside reverse
transcriptase inhibitors
620
- non-steroidal anti-inflammatory
drugs 357–8, 702
- North American Indian
cholestasis 212–13
- nor*-ursodeoxycholate 116
- NOTCH signaling pathway 6
Alagille syndrome 228–31
bile duct development 230
cardiovascular development
230–1
epidermal growth factor role
229
hepatoblastomas 750
hepatocellular carcinoma 750
- NOTCH2* mutations, Alagille
syndrome 216, 227–9
genetic testing 231
genotype–phenotype
correlation 230
identification 229
- NPC1* and *NPC2* mutations,
Niemann–Pick disease
type C 555
- Ntcp* 20
- nuclear factor-kappaB 410
- nuclear receptor(s) 15
activation by bile acids 26
bile salt transport regulation 21
cholestasis 26–7
nuclear receptor agonists 117, 432
nucleoside/nucleotide analogues
HBV treatment 286*t*, 287–8
mitochondrial hepatopathies
620
- 5'-nucleotidase 88, 92
- nutritional assessment in
cholestasis 124–6
- nutritional support
Alagille syndrome 228
following Kasai procedure 168
PFIC 206, 211
- obesity
bariatric surgery 646
cholesterol gallstone formation
258
- non-alcoholic fatty liver
disease association 631,
633, 637–8
- OC2 transcription factor 6
- octreotide 79
- oleic acid 592
- omega-3 fatty acids
239–40
- omega-6 fatty acids 239–40
- oncostatin M receptor 5
- opioid antagonists 120–1
- optic disk drusen 225
- oral contraceptives 353
- organic acidurias 387*t*
laboratory testing 390, 391*t*
newborn screening 397–8
- organic anion transporting
polypeptide 2 180
- oriental cholangitis 685*f*
- ornithine 12
- ornithine carbamoyltransferase
deficiency 97
- ornithine decarboxylase 10
- ornithine transcarbamylase
deficiency 396, 667
- ornithine translocase deficiency
667
- osteocalcin 134
- osteoporosis
in Alagille syndrome
222
in transferase deficiency
galactosemia 441
- oval cells 7
- oxidative phosphorylation 604
defective 603–4
- Δ^4 -3-oxosteroid 5 β -reductase
(*AKR1D1*) deficiency
578–9
- ursodeoxycholic acid
treatment 115
- Δ^4 -oxosteroid reductase
deficiency 502–3
- oxysterol 7 α -hydroxylase
(*CYP7B1*) deficiency
575–6
- oxytocin, neonatal jaundice
association 186
- pancreas
cystic disease 712–14
tyrosinemia 537
- pancreatic enzyme replacement
therapy 431
- pancreatic insufficiency, bone
marrow abnormalities
and liver involvement
see Pearson
marrow–pancreas
syndrome
- pancreatitis, acute liver failure
complication 46
- para*-aminobenzoic acid test
96–7
- paracetamol *see* acetaminophen
- paramyxovirus
acute liver failure in children
38
neonatal hepatitis 148
- parasitic diseases of liver 682–8
ascariasis 256, 684–5, 685*f*
capillariasis 685
echinococcal disease 684
Entamoeba histolytica
infection 674, 682–4,
683*f*
liver fluke 687*f*, 687–8
malaria 688
schistosomiasis 71, 685–7, 686*f*
toxocariasis 685
- parenteral nutrition *see also* total
parenteral nutrition
amino acid component 239
calorie load 242
excess 239
cycling 242
intestinal failure 234
management 241
intestinal failure-associated
liver disease 239–41
lipid emulsions 239–41
composition 240*t*
modification 242–3, 243*f*
non-lipid factor modification
242
- partial biliary diversion
hyperlipidemia treatment 123
pruritus treatment 121
- parvovirus B19
acute liver failure in children
38
neonatal hepatitis 148
- pathogen-associated molecular
patterns (PAMP) 41
- pattern-recognition receptors 41
- Pearson marrow–pancreas
syndrome 614–16
clinical features 616
diagnosis 616
pathogenesis 615–16
- pediatric acute liver failure
see acute liver failure in
children
- Pediatric Acute Liver Failure
Study Group
entry criteria for longitudinal
cohort study 32
etiology 33*t*
- Pediatric End-stage Liver Disease
(PELD) scoring system
59, 764–5, 765*f*
outcomes on waiting list 766
- pemoline 358
- penicillamine *see*
D-penicillamine
- penicillins 358
- Penicillium marneffei* infection
689
- perforins 379
- perihepatitis 676

Index

- perinuclear anti-neutrophil cytoplasmic antibodies (pANCA) 313
- peritoneovenous shunting in ascites 61
- peroxins 649
- peroxisomal disorders 581–2, 649, 655–61
- biochemical assays 655
 - biochemical defects 656*t*
 - clinical manifestations 657–60
 - diagnosis 581–2, 660–1
 - molecular tools 655–61
 - hepatic abnormalities 657*t*
 - putative mechanisms 660
 - impaired fatty acid beta-oxidation 652–3
- peroxisomal enzyme deficiencies 656, 657*t*
- clinical manifestations 658–60
- peroxisome biogenesis disorders 650, 652–3, 655–6, 657*t*
- clinical manifestations 657–8
 - phytanic acid metabolism 653
- presentation to hepatologist 661
- treatment 582, 661
- peroxisomal matrix proteins 649–50
- peroxisomal membrane proteins 649
- peroxisome proliferator activator receptor family 587–8, 651
- peroxisome proliferator-activated receptor coactivator 1*a* (*PGC1A*) 12
- peroxisome proliferator-induced carcinogenesis 651
- peroxisomes 649
- biogenesis 649–50
 - metabolic pathways 651–5, 652*f*
 - amino acids 654–5
 - bile acid synthesis 653
 - catalase 655
 - cholesterol biosynthesis 654
 - ether lipid biosynthesis 654
 - isoprenoid biosynthesis 654
 - α -methylacyl-CoA racemase 653–4
 - alpha-oxidation 653
 - beta-oxidation 653
 - morphology 650*f*
 - ontogenesis 660
 - proliferation 650–1
 - transmembrane proteins 651
- Peutz–Jeghers syndrome 252
- PEX mutations 649–50
- PFIC *see progressive familial intrahepatic cholestasis types*
- phenobarbital
- cholestasis treatment 116
- Crigler–Najjar syndrome treatment 195
- drug-induced liver disease 358
- hyperlipidemia treatment 123
- neonatal jaundice treatment 190
- pruritus treatment 121
- phenylalanine dietary control in tyrosinemia 539–40, 543
- 4-phenylbutyric acid 415
- phenylketonuria 529–30
- HNF1*a* deficiency 5
- phenytoin 358–9
- phosphate
- in cholestasis 134–5, 137
 - glycogen storage disease type IA 452
 - inorganic in hereditary fructose intolerance 444–5
 - hypophosphatemia 446
- phosphoenolpyruvate carboxykinase 10, 12
- phospholipid 13
- phosphomannomutase 2
- deficiency 706–7
- phosphomannose isomerase deficiency 706
- phosphoribosyl pyrophosphate 451
- phosphotransferase in mucopolipidosis types II and III 563–4
- phototherapy 189*f*
- Crigler–Najjar syndrome treatment 195
 - neonatal jaundice 188–9
- p*-hydroxyphenylpyruvate oxidase 12
- phyloquinone *see* vitamin K
- phytanic acid 653–4
- phytol 660
- phytosterols 240–1
- Pima Indians, gallstone disease 258*f*, 258
- pioglitazone 645
- pipecolic acid 654–6
- Piper methysticum* (kava) 42
- PKD1* mutations (polycystic kidney disease) 721, 724–5
- PKD2* mutations (polycystic kidney disease) 721, 724–5
- PKHD1* (polycystic kidney and hepatic disease 1) mutations 712, 715, 725
- plasmapheresis/plasma exchange, acute liver failure 47
- plasminogen activator inhibitor 1 424–5
- Plasmodium* 688
- platelets
- in cirrhosis 60
 - dysfunction in glycogen storage disease type IA 452
- PLUTO (Pediatric Liver Unresectable Tumor Observatory) 728
- pneumococcal infections 678
- Pneumocystis jiroveci* in liver transplantation 777
- PNPLA3* mutations 635
- POLG1* (polymerase gamma) mutations 613
- POLG1* disease 611
- Alpers–Huttenlocher syndrome 614
- polyclonal anti-CD3 antibodies 382
- polycystic liver disease cysts 722*f*
- von Meyenburg complexes 721
- polycystin 1 721, 725
- polycystin 2 721, 725
- polycythemia in neonatal jaundice 186
- polysplenia syndrome 105, 155–6
- polyunsaturated fatty acids 239–40
- Pompe disease *see* glycogen storage disease, type II
- porcelain gallbladder 252
- porphobilinogen 510
- in acute intermittent porphyria 516–17
 - in variegate porphyria 520
- porphyria(s) 509
- acute 512–13
 - animal models 523–4
 - classification 512–13
 - clinical features 512*t*
 - cutaneous 512–13
 - diagnosis 509, 513
 - drug treatment 515*t*
 - dual 523
 - erythropoietic 509, 512–13, 521–3
 - hepatic 509, 512, 514–21
 - homozygous forms 516*t*
 - laboratory findings 512*t*
 - subclinical 513
 - X-linked protoporphyria 521–2
 - see also* acute intermittent porphyria; congenital erythropoietic porphyria; hepatoerythropoietic porphyria; variegate porphyria
- porphyria cutanea tarda 517–19
- clinical features 518
- diagnosis 518
- homozygous type 2 518–19
 - susceptibility factors 518
- porphyrin 510
- porphyria diagnosis 509
- portal hypertension 68–85
- ascites 60, 69, 74
 - associated diseases 69*t*
 - bile duct ligation model 69
 - biliary atresia 75
 - biliary tract disease 70–1
 - cardiac output 71–2
 - cavernous transformation 70
 - cirrhotic 716
 - clinical features 54, 55*t*
 - clinical manifestations 73–4
 - pulmonary hypertension 74
 - splenomegaly 73
 - variceal hemorrhage 73, 76*f*
 - vascular markings 73
- congenital hepatic fibrosis 715–16
- cystic fibrosis 431
- decompression 69
- definition 68
- diagnostic evaluation 75–7
- endoscopy 76
- endothelin-1 71
- etiology 70
- experimental models 69
- Gaucher disease 549
- hemodynamic changes 71–3
- hepatic encephalopathy 69
- hepatocellular disorders 71
- hepatopulmonary syndrome 69, 73–4
- hepatorenal syndrome 69, 74
- idiopathic copper toxicosis 490
- intrahepatic causes 70–1
- intrinsic cardiac responses 72
- liver transplantation 68
- natural hypertension 74–5
- nitric oxide role 72
- non-cirrhotic 716
- pathophysiology 69–73
- fluid mechanics 69–70
 - increased vascular resistance 70–1
- portal vein obstruction 75
- portal vein stenosis model 69
- selective angiography 77
- serotonergic effects 72
- signs/symptoms 68–9
- splenic vein obstruction 70
- sympathetic tone alterations 72
- therapy 77–84, 716
- beta-blockers 77–8
 - emergency 78–81
 - endoscopic band ligation therapy 78, 80*f*, 81*f*
 - endoscopic emergency 79
 - esophageal transection and devascularization 81

Index

- interventional radiologic emergency 81
 - liver transplant 81
 - mechanical emergency 79–80
 - meso Rex bypass 84*f*, 84
 - pharmacologic emergency 79
 - portosystemic shunting 83*f*, 83–4
 - pre-primary prophylaxis 77
 - primary prophylaxis 77–8
 - secondary prophylaxis 81–4
 - surgical emergency 81
 - ultrasonography 76
 - variceal hemorrhage 73, 76 therapy 77–84
 - vascular resistance increase 70–1
 - vasoactive substances 71
 - vasodilatation 72
 - veno-occlusive disease 71
 - portal systems 68
 - portal triad development 2
 - portal vein
 - anatomy 68*f*
 - developmental abnormalities in biliary atresia 160–1
 - extrahepatic obstruction 75
 - portal vein thrombosis/stenosis
 - Kasai procedure complication 167
 - liver transplantation complications 779–80
 - portocaval shunting, glycogen storage disease type IA 454
 - portopulmonary hypertension 55, 74, 168
 - portosystemic shunting
 - ammonia levels 97
 - bile acid elevation 96
 - portal hypertension therapy 83–4
 - positive end-expiratory pressure 694
 - positive inspiratory pressure 694
 - posterior embryotoxon, Alagille syndrome 223–5, 224*f*, 227
 - posterior reversible encephalopathy syndrome 784
 - postprandial state, bile acid elevation 96
 - pre-eclampsia 600
 - pregnancy *see also* acute fatty liver of pregnancy; intrahepatic cholestasis of pregnancy
 - cholesterol gallstones 257, 259
 - fatty acid oxidation disorders 600
 - tyrosinemia 543
 - Wilson disease 486–7
 - pregnane X receptor (PXR) 15, 117
 - activation by bile acids 26
 - gallstone formation
 - association 259
 - pruritus 119
 - prematurity
 - intestinal failure-associated liver disease risk factor 237–8
 - neonatal jaundice 187
 - primary biliary cirrhosis
 - fatigue 122
 - tauroursodeoxycholic acid therapy 116
 - ursodeoxycholic acid therapy 114
 - primary hyperoxaluria type I 654, 656
 - clinical findings 659
 - diagnosis 659
 - management 659
 - combined liver–kidney transplant 659, 661
 - pathogenesis 659
 - primary sclerosing cholangitis 322
 - animal models 333–4, 334*f*
 - autoimmune hepatitis overlap 314–15, 316*t*, 324–6, 326*f*
 - management 318
 - bile acid elevation 96
 - bile duct disease classification 332*t*
 - biopsy 329–32
 - CFTR* mutation 334
 - cholangiocarcinoma
 - complication 337
 - cholangiography 337
 - clinical features 327
 - in congenital hepatic fibrosis 716
 - definition 322
 - diagnosis 328–9
 - epidemiology 324*t*, 326–7
 - gut lymphocyte homing hypothesis 333
 - histopathology 325*f*, 329–32, 330*f*
 - HLA* genes 333, 337
 - immunopathogenesis 332–3
 - incidence 326
 - inflammatory bowel disease
 - association 326–7, 330*f*
 - laboratory findings 324*t*, 327–8
 - leaky gut hypothesis 333
 - liver transplantation 336
 - prognosis 337
 - nor*-ursodeoxycholate therapy 116
 - pathogenesis 332*f*, 332–4
 - prognosis 336–7
 - small-duct 332
 - prognosis 337
 - treatment 334–6, 335*t*
 - surgical 336
 - ursodeoxycholic acid therapy 114
 - pristanic acid 653–4, 656
 - progressive familial intrahepatic cholestasis (PFIC)
 - 199–213, 200*t*
 - bile acid
 - concentration 584
 - elevation 96
 - enterohepatic circulation interruption 206–7
 - gamma-glutamyltransferase levels 92
 - genes 104, 107, 199
 - liver transplantation 207, 761
 - partial biliary diversion 121
 - pharmacological management 207
 - surgical management 206–7
 - treatment 206–7
 - ursodeoxycholic acid therapy 115
 - progressive familial intrahepatic cholestasis, type 1 (PFIC1; *FIC1* disease) 92, 115, 199–204, 200*t*
 - animal models 203
 - black pigment gallstones 256
 - clinical features 199–201, 584*t*
 - FIC1* protein 203*f*, 203–4
 - genetics (*FIC1*) 202
 - expression 199–201
 - mutations 202
 - histopathology 201–2, 202*f*
 - laboratory findings 201, 584
 - pathophysiology 203–4
 - ultrastructural pathology 202*f*
 - progressive familial intrahepatic cholestasis, type 2 (PFIC2; *BSEP* deficiency) 25, 92, 104, 115, 200*t*, 204–6
 - animal models 206
 - clinical features 204, 584*t*
 - genetics 205
 - histopathology 204–5
 - laboratory findings 204, 584
 - malignancy risk 204
 - normal gamma-glutamyltransferase cholestasis 207
 - pathophysiology 205–6
 - ultrastructural pathology 205*f*
 - progressive familial intrahepatic cholestasis, type 3 (PFIC3; *MDR3* deficiency) 25, 92, 115, 200*t*, 207–11
 - biliary phospholipid concentration 208–9
 - clinical features 208
 - genetics 210
 - histopathology 209*f*, 209–10
 - laboratory studies 208–9
 - liver transplantation 208
 - neonatal sclerosing cholangitis 325
 - pathophysiology 210*f*, 210–11
 - treatment 211
 - proinflammatory cytokines 695
 - propylthiouracil 35
 - drug-induced liver disease 359
 - protease inhibitors 620
 - protective protein/cathepsin A 558
 - protein C deficiency 697
 - protein requirements in cholestasis 126–7
 - protein S deficiency 697
 - prothrombin mutations 697
 - prothrombin time 88, 93–4
 - reference normal values 94*t*
 - protoporphyria
 - see also* erythropoietic protoporphyria (EPP)
 - X-linked 521–2
 - protoporphyrin
 - erythropoietic protoporphyria 522
 - levels in variegate porphyria 520
 - protoporphyrinogen oxidase 511
 - variegate porphyria 520
 - homozygous dominant 520
- Prox1 transcription factor 3
- pruritus 118–22
 - Alagille syndrome 217, 226–8
 - autotaxin role 119
 - ileal exclusion 121–2
 - nasobiliary drainage 122
 - non-absorbable ion exchange resin therapy 119–20
 - opiate receptor system 119, 122
 - opioid antagonist therapy 120–1
 - partial biliary diversion 121
 - pathogenesis 118–19
 - PFIC1 200, 206
 - PFIC2 204, 206
 - phenobarbital therapy 121
 - rifampicin therapy 120
 - symptoms 118
 - treatment 119–22
 - ursodeoxycholic acid therapy 121- Pseudomonas*, acalculous cholecystitis 250
- pseudoparkinsonism in Wilson disease 473
- pseudosclerosis in Wilson disease 473–4
- pseudo-TORCH syndrome 149–50

Index

- pseudo-Zellweger syndrome 581–2
- pulmonary arteriovenous shunting 74
- pulmonary artery anomalies in Alagille syndrome 219–20, 220f
- pulmonary hypertension 74
- purine synthesis in glycogen storage disease type IA 451
- PXR *see* pregnane X receptor
- pyogenic liver abscess 673–5
 - clinical manifestations 674
 - diagnosis 674
 - etiology 674
 - management 674f, 674–5
- pyrrolizidine alkaloids 489
- pyruvate 12
 - gluconeogenesis 11–12
 - mitochondrial metabolic pathway 605
- pyruvate carboxylase deficiency 390
 - urea cycle disorder differential diagnosis 668
- pyruvate dehydrogenase disorder 390
- pyruvate kinase deficiency 255
- Q fever 682f, 682
- rapamycin 319
- reactive oxygen species 603–4
- rectal varices in portal hypertension 73
- red blood cells, enzyme and membrane defects in neonatal jaundice 186
- Refsum disease *see* infantile Refsum disease
- regeneration of liver 1
- regulatory T lymphocytes (Treg cells)
 - autoimmune hepatitis 312
 - in biliary atresia 160
 - immunologic tolerance 370–1
- renal anomalies in Alagille syndrome 225
- renal tubular acidosis 446
- renin–angiotensin system
 - ascites 57, 60
 - hepatorenal syndrome 62–3
- reovirus 3 infection
 - in biliary atresia 158
 - in neonatal hepatitis 148
- respiratory chain complex
 - enzymes 605f
 - activity measurement 623
 - deficiencies 611
 - polypeptide subunits 604t
- respiratory chain defects 605
- diagnosis 621
 - definitive tests 622–4
 - prenatal 626–7
 - histopathological investigations 623
 - imaging 623
 - molecular analysis 623–4
 - screening tests 621–2, 622t
 - treatment 624–6, 625t
- retinoid X receptor alpha (RXRa) 21, 651
- retinoids 359
- retinol 127–8
- retinol:retinol binding protein ratio 129
- reverse transcriptase inhibitors 620
- Reye syndrome 617
 - ammonia levels 97
 - aspirin hepatotoxicity 351
 - clinical presentation 618
 - in fatty acid oxidation disorders 587, 593
 - in juvenile idiopathic arthritis 702
 - in mitochondrial hepatopathy 618–19
 - pathology 360–1, 361f, 618f, 619
 - salicylate association 619
- Rhesus incompatibility in neonatal jaundice 185–6
- Rhett syndrome 256
- rhizomelic chondrodysplasia punctata 654
 - hepatic abnormalities 660
 - type I 655–6
- ribavirin
 - HCV treatment 303–4
 - adverse effects 305
 - response to therapy 305–7
 - HEV treatment 272
- ricketsial disease 682f, 682
- rifampin (rifampicin)
 - Gilbert syndrome diagnosis 193
 - pruritus treatment 120
- risperidone 359
- rituximab 382–3
- Rocky Mountain spotted fever 682
 - gallbladder inflammation 250
- rotavirus group C in biliary atresia 158
- Rotor syndrome 192t, 195–6
- Roux-en-Y
 - choledochojejunostomy, choledochal cyst management 172–3, 174f
- roxithromycin 35–6
- rubella virus 144–5
- salicylates
 - hepatotoxicity 351
 - Reye syndrome association 619
- Salmonella paratyphi* 677
- Salmonella typhi* 677
- salpingitis with perihepatitis 676
- saposins 546
- sarcoidosis 706
- sarcoma, undifferentiated/
 - embryonal 741–2, 748f
 - chromosomal abnormalities 752
 - genetics 751
- schistosomiasis (*Schistosoma*) 685–7
 - clinical features 686f, 686
 - diagnosis 686–7
 - epidemiology 685–6
 - laboratory findings 686
 - portal hypertension 71
 - treatment 687
- Schwalbe ring in Alagille syndrome 223–4, 224f
- scleroderma 704
- sclerosing cholangitis 322–38
 - see also* primary sclerosing cholangitis
 - associated conditions 322–4
 - autoimmune 322, 326
 - biopsy 329–32
 - cholangiography 337
 - clinical features 327, 328t
 - definition 322
 - diagnosis 328–9
 - epidemiology 324t, 326–7
 - histopathologic stages 330, 331f
 - histopathology 325f, 329–32, 330f
 - imaging 328f, 328–9
 - incidence 326
 - inflammatory bowel disease
 - association 322, 324, 326–7, 330f
 - colorectal cancer risk 337
 - laboratory findings 324t, 327–8
 - Langerhans cell histiocytosis
 - association 324f
 - liver transplantation 336
 - prognosis 337
 - microorganism association 333
 - neonatal 325
 - opportunistic infections in development 373–4
 - pathogenesis 332f, 332–4
 - primary immunodeficiency
 - hepatic complication 371–3, 377t
 - prognosis 336–7
 - progression rate 336–7
 - secondary 322
 - serologic markers 329
 - spectrum of disease 322–6, 323t
 - survival 336–7
 - treatment 334–6, 335t
 - surgical 336
- secondary iron overload 500–2
 - biopsy 502
 - pathophysiology 500–1
 - treatment 501f, 501–2
- seizures
 - acute liver failure 45
 - calcineurin inhibitor toxicity 784
- selenium in cholestasis 135
- Sengstaken–Blakemore tube 79–80
- sepsis 673f
 - acalculous cholecystitis 250
 - intestinal failure-associated
 - liver disease risk factor 238, 241
 - systemic 38
- sepsis-associated cholestasis 27–8, 238
- septo-optic dysplasia 704
- septum transversum
 - mesenchyme 1f, 2–3
- serine 12
- serpin(s) 400, 402
- SERPINA1 protein 424–5
- serpin–enzyme complex
 - receptors 406
- Serratia* acalculous cholecystitis 250
- severe combined immunodeficiency 375
- sexually transmitted infections 267
- short bowel syndrome 234t, 234
 - malabsorption 238
 - necrotizing enterocolitis 238
 - survival 235f
- short stature *see also* growth failure
 - Alagille syndrome 222
- short-chain 2,3 enoyl-CoA hydratase 591
- short-chain 3-ketoacyl-CoA thiolase 591
- short-chain acyl-CoA dehydrogenase 590
- short-chain acyl-CoA dehydrogenase deficiency 595
- sialidosis 557–8
- sickle cell disease 698
 - acute hepatic sequestration 698
 - black pigment gallstones 255, 262
 - cirrhosis 698
 - complications 698
 - secondary iron overload 500–1
 - sickle cell hepatopathy 698
 - transfusion-related
 - hemosiderosis 698
- siderosis
 - extrahepatic in neonatal hemochromatosis 503–5
 - transfusion-related
 - hemosiderosis 698

Index

- simvastatin 123
- sinusoidal obstruction syndrome
 - see veno-occlusive disease (VOD)
- sinusoids, in cirrhosis 53
- Sjögren syndrome 149, 703–4
- gallbladder hydrops 249
- small bowel bacterial overgrowth 238
 - ileocecal valve absence 239
- small heterodimer partner 21
- α -smooth muscle actin 53
- smooth muscle antibody (SMA) 311–12
- sodium benzoate 669–70
- sodium phenylacetate 669–70
- sodium retention in cirrhosis 60–1
- sodium taurocholate
 - cotransporting polypeptide 20, 24
- solitary benign bile duct cyst 739
- solitary nonparasitic cyst 711
- soluble liver antigen/liver-pancreas antigen 312
- somatosensory evoked potentials 188
- somatostatin 79
- sonic hedgehog pathway 749–50
- Sox17 transcription factor 7
- space of Disse 53
- specification 1f, 2, 4t
 - signals from adjacent tissues 2–3
- sphingolipid(s) 546
- sphingolipidoses 546–54
- spider angiomas in cirrhosis 54
- spirochetal infection 38
- spironolactone
 - amenorrhea in adolescents 137
 - ascites treatment 61
- splenic vein obstruction in portal hypertension 70
- splenomegaly 73
- spontaneous bacterial peritonitis
 - in ascites 60–2, 62t
 - in hepatorenal syndrome 63
 - management 62
 - mortality rate 62
 - organisms 62
 - symptoms 62
- staphylococcal infections 678
 - chronic granulomatous disease 381
 - toxic shock syndrome 678
- Staphylococcus aureus* 381
- steatorrhea in cholestasis 126
- steatosis
 - choleine deficiency 239
 - in cystic fibrosis
 - clinical presentation of liver injury 426f, 426–7
 - pathogenesis of liver injury 424
 - treatment 430
 - diffuse 43
 - intestinal failure-associated liver disease 235–6, 239
- stellate cells 1–2, 53
 - drug-induced injury in cells 344
 - liver injury in cystic fibrosis 423–4
 - in progressive fibrosis 118
- stem cell transplantation
 - graft-versus-host disease complication 701–2
 - hepatic complications 699–702
 - pharmacological manipulation of immune response 382
 - prior liver disease 699
 - tyrosinemia 543
 - veno-occlusive disease 699–701
- sterol 27-hydroxylase deficiency (CYP27A1)
 - see cerebrotendinous xanthomatosis
- Still disease see juvenile idiopathic arthritis
- streptococcal infections 678
- Streptococcus viridans* 250
- stromal–epithelial tumor, nested 745f
- succinylacetone 527
- SUCLG1 mutations 613
- sudden infant death 596
 - medium chain acyl-CoA dehydrogenase deficiency 594
- sulfonamides 359–60
- sulfotransferases 16–17
- sulindac 357
- sunflower cataract 472
- syncytial giant cell hepatitis 38
- syphilis 680–1
 - congenital 680
 - acute liver failure in children 38
 - neonatal hepatitis 142
- systemic disease 707
 - see also Budd–Chiari syndrome
 - amyloidosis 703, 706
 - circulatory failure 695–6
 - collagen vascular disease 702–4
 - Behçet syndrome 704
 - dermatomyositis 704
 - juvenile idiopathic arthritis 702–3
 - Kawasaki syndrome 704
 - scleroderma 704
 - Sjögren syndrome 703–4
 - systemic lupus erythematosus 703
 - congenital disorders of glycosylation 706–7, 707t
 - endocrine disorders 704–5
 - heart disease 695–6
 - hematologic disorders 698–9
 - hepatic dysfunction in intensive care 694
 - hepatic venous outflow obstruction 696–8
 - infection 694–5
 - nutritional disorders 705–6
 - sarcoidosis 706
 - stem cell transplantation 699–702
 - systemic inflammatory response syndrome 42
 - systemic lupus erythematosus 703
 - systemic sepsis 38
- T-cells 41
 - autoreactive in autoimmune hepatitis 312
- tacrolimus
 - autoimmune hepatitis management 318
 - in liver transplantation 774
- taurine 13
- tauroursodeoxycholic acid 113, 116
- Tbx3 transcription factor 3
 - hepatocyte differentiation 5
- telaprevir 307
- telbivudine 288
- telithromycin 353
- tenofovir disoproxil fumarate 288
- terlipressin 79
- tetralogy of Fallot in Alagille syndrome 219–20, 220f
- thalassemia
 - black pigment gallstones 255
 - neonatal jaundice 186
 - secondary iron overload 500–1
 - transfusion-related hemochromatosis 698
- T helper cells 41
- 6-thioguanine hepatotoxicity 351
- thrombophilia, inherited 697
- thrombospondin-1 725
- thymidine kinase 10
- thyroxine in fetal circulation 10
- tissue inhibitors of metalloproteinase 424–5
- TK2 mutations 613
- tocopherol 131–2
- tocotrienols 131–2
- total parenteral nutrition (TPN)
 - black pigment gallstones 255–6
 - glycogen storage disease type IA 453
 - associated cholestasis 28, 234
 - see also in intestinal failure-associated liver disease
 - ursodeoxycholic acid therapy 115
- toxic shock syndrome 678
- toxocariasis (*Toxocara canis*) 685
- Toxoplasma gondii* 143
- toxoplasmosis (*Toxoplasma*) 143
- TPN see total parenteral nutrition
- transcription factors
 - FOXA 3, 5
 - GATA 3
 - GATA6 3
 - Hhex 3, 6–7
 - HNF1 α 5
 - HNF1 β 3, 6–7
 - HNF6 6–7
 - OC2 6
 - Prox1 3
 - Sox17 7
 - Tbx3 3, 5
 - Yap1 5
- transferase deficiency
 - galactosemia 435–41
 - biochemical features 437–9
 - brain pathology 438–9
 - cataracts 437–9
 - clinical presentation 437
 - cognitive impairment 441
 - diagnosis 439–40
 - Escherichia coli* sepsis association 437
 - galactose-free diet 440–1
 - genetics 439
 - intestinal symptoms 439
 - kidney changes 438–9
 - laboratory findings 437
 - lenticular changes 438–9
 - liver changes 438
 - molecular basis 436–7
 - mutations 436–7
 - osteoporosis association 441
 - ovarian failure 439
 - pathogenesis 437–9
 - pathology 439
 - prognosis 441
 - screening 440
 - treatment 440–1
 - in utero assay 440
 - variants 439–40
- transferrin 494
 - saturation screen 497
- transferrin receptor 2 494
 - iron absorption role 495f
- transforming growth factor- β (TGF β) 3–5
 - biliary differentiation induction 6
 - fibrosis 53
 - miR-30 in signaling regulation 6
 - TGF β ₁ 725
- transforming growth factor- α (TGF α) 723
- transfusion see blood transfusions
- transfusion transmitted virus 147
- transient elastography in cystic fibrosis 429

Index

- transient hyperammonemia of the newborn 668
transient hyperphosphatemia of infancy 91
transient hypertyrosinemia of the newborn 529
transjugular intrahepatic portosystemic shunt
ascites treatment 61
hepatopulmonary syndrome 55
variceal hemorrhage in portal hypertension 81, 82f
transporter symbol SLC21A6 180
trans-sulfuration pathway 13
travel
HAV association 266–7
HEV association 271
Treg cells (regulatory T lymphocytes) 160
Treponema pallidum in neonatal hepatitis 142
triacylglycerol 13
tricarboxylic acid (TCA) cycle 605–6
Trichosporon hepatitis 689
triethylene tetramine dihydrochloride (trientine) 484–5
trifunctional protein 591f, 591
deficiency 594
triglyceride(s) 13
glycogen storage disease type IA 450–1
triglyceride lipase 94
triheptanoate in fatty acid oxidation disorders 600
triiodothyronine fetal circulation 10
trisomy 17–18 syndrome (trisomy E) 149
trisomy 18 247–8
tuberculosis 679–80
opportunistic infection in HIV 149
tuberculous hepatitis 142–3
tularemia 678
tumors of liver 728t, 728–56
benign vascular tumor
incidence 728
clinical presentation 728, 730–3, 733t
diagnosis 733–4, 736t
dissemination 735f
epidemiology 728–9
etiology 729–30
genetic syndrome association 729t, 730
imaging 734f
liver transplantation 755, 763–4
malignant 728
metabolic disease 732f
metastases 734, 735f, 737
pathology 736–44, 739t
prognosis 752–3
staging 734–5, 736f, 736t, 739t
treatment 753–6
chemotherapy 754–5
preoperative chemotherapy 753
radiation therapy 755
surgical 753–4
transcatheter arterial chemoembolization 755
vascular 751–2, 754
see also *named tumor types*
typhoid, acalculous cholecystitis 250
typhoid hepatitis 677–8
tyrosine 12
dietary control in tyrosinemia 539–40, 543
metabolism 527f
tyrosinemia 526–44
acute liver crises
clinical findings in non-nitisinone-treated patients 530
management 540
acute liver failure in children 36, 40
carrier screening 529
chronic liver disease
clinical findings in non-nitisinone-treated patients 530
management 540–1
cirrhosis 533–5, 540–1
clinical findings in non-nitisinone-treated patients 530–3
chronic liver disease 530
hepatic nodules 533–5, 536f, 540
liver crises 530
neurologic crises 531–3
renal disease 533
diagnosis 528–9
differential diagnosis 529
genetics 527–8
hepatoblastoma 531, 537, 541
hepatocellular carcinoma 530–1, 535, 541
imaging 533–5
kidney 535
liver 533–5
pancreas 535
liver cell dysplasia 535–7
liver disease
chronic 530, 535–7
fulminant 535
liver transplantation 531t, 762
management 537–43, 539f
acute liver crises 540
chronic liver disease 540–1
dietary therapy 539–40, 543
gene therapy 542–3
hepatocyte transplantation 542–3
liver transplantation 531t, 540–2
neurologic crises 541
nitisinone 533, 537–9, 543, 762
renal involvement 541–2
molecular diagnosis 528–9
neurologic crises
clinical findings in non-nitisinone-treated patients 531–3
management 541
pathology 535–7
heart 537
kidney 537
liver 532f, 535–7, 536f
pancreas 537
peripheral nerves 537
pathophysiology 526–7
pregnancy 543
prenatal diagnosis` 529
renal involvement 534t
clinical findings in non-nitisinone-treated patients 533
management 541–2
screening 527–8
carrier 529
neonatal 529
transient neonatal 12
type II 529
type III 529
UDCA see ursodeoxycholic acid
UDP-galactose-4-epimerase
deficiency galactosemia
see epimerase deficiency galactosemia
UGT1 (UDP glycosyltransferase 1) mutations 180f
UGT1A (UDP glycosyltransferase 1A) mutations 16, 180
Crigler–Najjar syndrome 194
Gilbert syndrome 16, 180, 192–3
ulcerative colitis 326–7
ultrasonography
cystic fibrosis 428–9
neonatal cholestasis 107–8
ultraviolet light, pruritus treatment 122
unfolded protein response signaling pathway 410
unsaturated fatty acids 592, 593f
urea
production from ammonia 664–5
synthesis in fetal liver 13
urea cycle
ammonia detoxification/clearance 97
conditions affecting 666t
enzymes 665
genes 665t
hepatic components 664f
molecular aspects 665
stresses 666t
urea cycle disorders 88, 97, 387t, 396, 664–71
ammonia levels 97
classic 667
clinical presentation 665–7, 666t, 667t
delayed onset 666, 667t
diagnosis 667–8, 668t
differential diagnosis 668
future research direction 670–1
genetics 665t
hyperammonemia 668, 670
creatinine deficiency 671
rapid response 670
imaging 670–1
laboratory tests 667–8
liver transplantation 761
neonatal onset 665–6, 666t
treatment 668–70
arginine 670
catabolic state management 669–70
dialysis 668–9
emergency pharmacologic 669t, 669–70
goals 669t
liver cell transplantation 671
liver transplantation 670
long-term management 670
uridine diphosphate
glucuronosyltransferases 10, 16, 343
transferase deficiency
galactosemia diagnosis 439
urinary tract infections, neonatal hepatitis 142
urobilinogen, laboratory assessment 95–6
urobilinoids 182, 183f
uroporphyrin 521
uroporphyrinogen decarboxylase 511
porphyria cutanea tarda
activity in 518
mutations in 517–18
treatment 518–19
uroporphyrinogen synthase 510
congenital erythropoietic porphyria 521
ursodeoxycholic acid 113
Alagille syndrome 115
bile acid synthesis defect
treatment 115
biliary atresia treatment 115
cystic fibrosis
levels in 423
treatment 114–15, 430–2
gallstone dissolution 261–2

Index

- graft-versus-host disease
 - treatment 115, 702
- hepatic veno-occlusive disease
 - treatment 115
- hyperlipidemia treatment 123
- intestinal failure-associated
 - liver disease treatment 243
- low phospholipid-associated
 - cholelithiasis syndrome treatment 211
- PFIC treatment 115, 207, 211
- primary biliary cirrhosis
 - treatment 114
- primary sclerosing cholangitis
 - treatment 114
- pruritus treatment 121
- sclerosing cholangitis
 - treatment 334–5
- TPN-associated cholestasis
 - treatment 115
- valine 12
- valproic acid 35–6
 - drug-induced liver disease 360–2
- hepatotoxicity
 - Alpers syndrome association 362
 - carnitine serum levels 362
 - clinical features 360
 - investigations 361
 - mechanism 360–1
 - metabolites 361*f*, 361
 - mitochondrial
 - hepatopathies 619
 - mitochondrial beta-oxidation anomaly 361–2
 - pathology 361*f*
- variceal hemorrhage in portal hypertension 73, 76
- therapy 77–84
 - band ligation therapy 82–3
 - emergency 78–81
 - endoscopic band ligation therapy 78, 80*f*, 81*f*
 - endoscopic emergency 79
 - esophageal transection and devascularization 81
 - interventional radiologic emergency 81
 - liver transplant 81
 - mechanical emergency 79–80
 - pharmacologic emergency 79
 - portosystemic shunting 83*f*, 83–4
 - pre-primary prophylaxis 77
 - primary prophylaxis 77–8
 - sclerotherapy 82–3
 - secondary prophylaxis 81–4
 - surgical emergency 81
 - transjugular intrahepatic portosystemic shunt 81, 82*f*
- variegate porphyria 520
- vascular tumors 751–2
 - treatment 754
- vasopressin 79
- velaglucerase 551
- veno-occlusive disease
 - antineoplastic drug-induced 350–1
 - clinical course 700
 - diagnosis 700
 - herbal medication-induced 355
 - incidence 700
 - pathogenesis 700*t*, 700
 - prognosis 701
 - in stem cell transplantation 699–701
 - treatment 700–1
- vertebral abnormalities in
 - Alagille syndrome 220*f*, 221*f*, 221–2, 222*f*, 227
- very long chain acyl CoA dehydrogenase 589
- very long chain acyl CoA dehydrogenase deficiency 593–4
- vinca alkaloids 350
- viral hepatitis
 - acute liver failure 42
 - gallbladder hydrops 249
 - immunodeficiency 376
 - see also individual named hepatitis virus infections*
- viral infections
 - acute liver failure in children 38
 - biliary atresia 157–8
 - liver transplantation
 - febrile patient evaluation 777
 - risk 773, 776–7
 - see also hepatitis; viral hepatitis; individual named viral infections*
- visceral larva migrans 685
- visceral leishmaniasis 688
- vitamin(s)
 - deficiencies
 - in Alagille syndrome 228
 - of fat-soluble in chronic liver disease 65–6
 - in fatty acid oxidation disorders 600
 - fat-soluble
 - in cholestasis 124*f*, 127–34
 - deficiency in chronic liver disease 65–6
 - water-soluble in cholestasis 134
- vitamin A
 - in cholestasis 127–30, 128*f*, 129*t*
 - conjunctival impression cytology 129–30
 - deficiency in cholestasis 128, 130
 - drug-induced liver disease 359, 706
 - metabolism 128*f*
 - oral supplementation 130
 - relative dose response 128, 129*f*
 - status evaluation 128, 129*f*
 - supplementation following
 - Kasai procedure 168
- vitamin B supplementation 600
- vitamin D
 - in cholestasis 130–1
 - metabolism 130*f*
 - in PFIC2 204
 - supplementation following
 - Kasai procedure 168
 - toxicity 131
- vitamin D deficiency
 - in cholestasis 130–1, 137
 - in PFIC1 199–200
 - rickets 131*f*
 - supplementation 131
- vitamin E
 - in cholestasis 131–4, 132*f*
 - fibrosis treatment 118
 - functions 133
 - malabsorption 132
 - metabolism 132
 - status assessment 133
 - supplementation 133, 136
 - following Kasai procedure 168
 - in glycogen storage disease type IB 455
 - idiopathic copper toxicosis 491
 - non-alcoholic fatty liver disease treatment 645
 - Wilson disease 485–6
 - therapy monitoring 133–4
- vitamin E deficiency
 - in cholestasis 132*f*, 132
 - manifestations 132–3
 - neuromuscular involvement 132*f*
 - PFIC1 199–200
 - prevention of development 133
- vitamin E:lipid ratio 133–4
- vitamin K 134
 - supplementation following
 - Kasai procedure 168
- vitamin K deficiency 93, 134
 - coagulopathy 705
 - PFIC1 199–200
 - PFIC2 204
 - supplementation 134
- von Gierke disease *see* glycogen storage disease, type IA
- von Meyenburg complexes 721–2
- VPS33B mutations 212
- weight of liver, relative 10
- Wilms tumor 739, 747
- Wilson disease 465, 469–87
 - acute liver failure 37, 472, 481
 - alkaline phosphatase serum levels 91
 - aminotransferases chronic elevation 482
 - AST:ALT ratio 90
 - ATP7B mutations 465, 467*f*, 470
 - diagnostic molecular genetic testing 477–8
 - disease pathogenesis 470
 - black pigment gallstones 256
 - ceruloplasmin levels 470, 475–8
 - cirrhosis 472–3, 479, 481
 - clinical features 469*t*, 471*f*, 471–5
 - cardiac involvement 474–5
 - hematologic manifestations 474
 - hepatic symptoms 471–3, 472*t*
 - malignancy 473
 - neuropsychiatric symptoms 471, 473*t*, 473–4, 484
 - ocular symptoms 471*f*, 471–2
 - renal 474
 - skeletal 475
 - copper/copper levels 470–1, 475
 - brain 474
 - diagnostic 476–8, 480
 - histochemical stains 479–80
 - toxicity 468–9
 - diagnosis 475–82, 476*t*
 - asymptomatic siblings 482*f*, 482
 - ceruloplasmin levels 475–8
 - copper levels 476–8, 480
 - electron microscopy 480*f*, 480
 - hepatic presentation 475–80
 - histochemical stains 479–80
 - imaging 480–1
 - liver biopsy 477, 481
 - molecular genetic testing 477–8
 - neuropsychiatric presentation 480–1
 - ophthalmology 477–8, 480, 482
 - radiolabeled copper test 477
 - epidemiology 469–70
 - evaluation 57
 - Fanconi syndrome 475
 - fulminant 472, 479, 481
 - prognostic index 486*t*
 - gallstones 473
 - genetics 466–7, 470

Index

Wilson disease (cont.) hepatitis acute 472, 478–9, 481 chronic 472–3, 481 histopathology 478 <i>f</i> , 478–80, 479 <i>f</i> historical aspects 469 Kayser–Fleischer ring 471–2 laboratory findings 475 liver transplantation 481, 486 management 478 <i>f</i> , 482–7, 483 <i>t</i> ammonium tetrathiomolybdate 485 antioxidant therapy 485–6 copper chelation 465, 473, 483–5, 619	D-penicillamine therapy 483–4, 486–7 liver transplantation 481, 486 in pregnancy 486–7 surgical patients 487 triethylene tetramine dihydrochloride 484–5 vitamin E supplementation 485–6 zinc therapy 485 mitochondrial hepatopathy 619 pathogenesis 470, 619 in pregnancy 486–7 screening 482 <i>f</i> , 482 sunflower cataract 472 WNT signaling pathway 2–3	hepatoblast differentiation 6 hepatoblastomas 747–9 WNT/ β -catenin pathway, liver regeneration 54 Wolman disease 561 xanthomas in Alagille syndrome 122, 123 <i>f</i> , 217, 218 <i>f</i> , 226 in cerebrotendinous xanthomatosis 579 in cholestasis 122–3 in glycogen storage disease type 1A 450 X-linked adrenoleukodystrophy 582, 660 X-linked proliferative disease 380–1	X-linked protoporphyria 521–2 Yap1 transcription factor 5 <i>Yersinia enterocolitica</i> 678 Zellweger syndrome 581–2 clinical manifestations 657–8 hepatic abnormalities 660 histopathology 658 peroxisomal abnormalities 654–6 treatment 582, 658 zinc in cholestasis 135 deficiency 91 therapy in Wilson disease management 485
--	--	---	--